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ABSTRACT

ANALYSIS STRATEGIES FOR BIOACTIVE, POLAR FATTY AMIDES IN
COMPLEX SAMPLES

By
Erin Blaine Divito
December 2013

Dissertation supervised by Michael Cascio
Bioactive lipids are known to exert physiological effects and interact with
neuroreceptors. Little is known about the bioregulation of primary fatty acid amides,
though N-acyl glycines are thought to be their anabolic precursors. Chapter 1 details the
current metabolic, physiological, and receptor interactions of primary fatty acid amides
and their related congeners and reviews current strategies for isolation and detection.
Chapter 2 outlines mass spectrometry collision induced fragmentation assignments
pertaining to method development of multiple reaction monitoring detection of these
species. Chromatographic separation methods of fatty acyls, with a focus on primary fatty
acid amides and N-acyl glycines, are outlined in chapter 3 and these results are used to
develop a two dimensional liquid chromatography tandem mass spectrometry analysis
method. Multiple reaction monitoring was utilized as the detection mode due to the
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enhanced limit of detection obtained from mass filtering background and matrix
components. The implementation of our developed analytical separation and detection
approach for quantitation of these bioactive lipids in vertebrate samples and future
implications of primary fatty acid amide and N-acyl glycine analysis are reviewed in
chapter 4. In addition, the appendix summarizes a method for selective, sensitive multiple
reaction monitoring detection of palmitoylethanolamine, an N-acylethanolamine with
analgesic and anti-inflammatory properties.
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Chapter 1

Metabolism, Physiology, and Analyses of Primary
Fatty Acid Amides
Adapted from: Divito, E. B.; Cascio, M. Metabolism, Physiology, and Analysis of
Primary Fatty Acid Amides. Chemical Reviews. (In Press)
1.1 INTRODUCTION
Primary fatty acid amides (PFAMs) are a group of lipids that have been identified
as bioactive lipid signaling molecules.

In this introductory chapter we review the

progress in identifying metabolism pathways, pharmacological properties, and receptor
interactions for this group of lipids.

In addition, various modes of separation and

detection have been developed to study both their biological content and alterations in
their metabolism, and these studies are also reviewed.
Lipids are loosely defined as hydrophobic molecules, typically containing an acyl
chain or ring structure, that are soluble in organic solvents. Recently a new classification
system was developed allowing for a broad definition of lipids that is based on similarity
in structure and biosynthetic pathways1. This system ultimately divided lipid molecules
into eight different classes, including numerous subclasses. It is easily observed from the
number of subclasses in each category that lipids comprise a broad range of molecules.
A few subclasses of the fatty acyls group relevant to this review are shown in Table 1-1.
A new subclass of lipids, the PFAMs, has been recently identified. This group consists of
a carboxamide head group and an acyl tail of various length and unsaturation. The first
report of PFAMs was in luteal phase plasma reported in 1989 by Arafat and coworkers 2.
Since this initial discovery, many studies have been published on their interaction with
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various receptors, including the 5-hydroxytryptamine (5-HT)3-8, cannabinoid9, and ɣaminobutyric acid (GABA) receptors10,11.

Interactions of PFAMs with cannabinoid

receptors are still somewhat controversial, as oleamide has been shown to weakly
potentiate (1 µM) or to have no effect on cannabinoid receptors in
vitro12,13. Additionally, many observations of behavioral effects upon subcutaneous or
intravenous injection of oleamide (octahexanoamide, denoted C18:1 9) have been
reported.

These responses include analgesic and anti-anxiety14 phenotypes, sleep

induction15-17, and increased food uptake.18

There also is an implied link between

oleamide and mood due to the observed potentiation of 5-HT receptors (5-HTR) with
exogenous application of oleamide14,19.
Although studies indicate PFAMs are bioactive signaling molecules, little is
known about their metabolism or localization in vivo. This is possibly due to their low
concentrations in tissue and biological fluids, typically in the nM range 2,16,20,21, which
makes analyses challenging. Their structural similarity to other lipid subclasses and
occurrence of isomers within the subclass can make isolation and structural identification
more complicated.

This review will examine some of the progress made towards

identifying PFAM metabolic pathways, their physiology and receptor interactions, and
current methods of analyses.
.
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Lipid Subclass
Fatty Acids
(FA)

Common
Name
(CX:Yz)

Structure

Oleic acid
(C18:19)
Oleamide
(C18:19)

Primary Fatty Acid Amides
(PFAMs)

Erucamide
(C22:113)
Linoleamide
(C18:29,12)

N-acyl Glycines
(NAGs)

Oleoylglycine
(C18:19)

N-acyl Ethanolamines
(NAEs)

Anandamide
(C20:45,8,11,14)

Table 1-1. Representative structures from the FA, PFAM, NAG, and NAE
subclasses of lipids. The common name is given for each structure along with
the typical lipid abbreviation CX:Y z. C indicates the carbon acyl chain starting
from the head group position with X being the number of carbon atoms in the
chain. Y is the number of unsaturation points and z indicates the position(s) of
unsaturation. The orientation of unsaturated bonds are cis unless otherwise
(e.g., C18:19 trans).
1.2. noted
BIOSYNTHESIS
The identification of PFAMs in human plasma in 19892 went largely
unrecognized until 1995 when Cravatt et al.15 reported increased levels of three PFAMs
in the cerebral spinal fluid (CSF) of sleep deprived cats. This finding, in conjunction
with

several other reports on oleamide (C18:19) and 5-HTR interaction3-11, increased

interest in the anabolic pathways of PFAMs.

An enzyme involved in the post-

translational modification of peptides, peptidylglycine α-amidating monoxygenase
(PAM), converts peptidyl glycines to their active amidated form. Merkler et al.22 were
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the first to report that PAM also converts N-myristoylglycine (C14:0) to the primary
amide, myristamide. This led the authors to hypothesize that PAM could amidate other
fatty glycines to their corresponding primary amide form. In a subsequent work, a broad
range of fatty glycines, from formylglycine to linoleoylglycine, were converted to the
primary amide form by purified recombinant type A rat PAM23,24. The apparent affinity
of these substrates for PAM varied widely, but generally increased as the acyl chain
length of the substrate increased.

The Km for longer chain length substrates were

generally equal or greater than that of a previously characterized “good” peptide
substrate, D-Tyr-Val-Gly. Oxygen and glyoxylate levels were measured to quantitate
activity of PAM, and NMR studies confirmed the conversion of the fatty glycine to its
PFAM. During monitoring of oxygen and glyoxylate, oxygen levels depleted rapidly
while glyoxylate production, from the oxidative cleavage of the fatty glycine,
accumulated more slowly. This supported a hypothesis that the fatty glycine first goes
through an intermediate form before oxidative cleavage by peptidyl-α-hydroxyglycine αamidating lysase (PAL), the second domain of PAM. The intermediate was identified by
NMR analysis as N-acyl-α-hydroxyglycine23. In vitro reactions of PAM and various fatty
glycines were analyzed by liquid chromatography and UV detection, and the resulting
three peaks were identified as the fatty glycine, the N-acyl-α-hydroxyglycine, and the
PFAM. When a PAL inhibitor was added to the incubation mixture the levels of fatty
glycine and the intermediate N-acyl-α-hydroxyglycine increased and PFAM levels were
decreased as compared to the incubation mixtures without inhibitor 25. Similar results
were observed in N18TG2 mouse neuroblastoma cells26.

The authors proposed a

biosynthesis pathway where a fatty acid is converted to a fatty-CoA by acyl-CoA
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transferase.

The fatty-CoA then is converted to a fatty glycine by glycine N-acyl

transferase (GLYAT) and the fatty glycine proceeds to the PFAM through the actions of
PAM (see Scheme 1).
Mueller and coworkers have reported enzymatic conversion of both oleoyl-CoA
and oleoyl glycine to oleamide by cytochrome c27,28. In both cases, the presence of
oleamide was confirmed by TLC separation, liquid chromatography with UV detection,
and tandem mass spectrometry. In regard to conversion of oleoyl-CoA to oleoyl glycine,
maximal conversion rates were observed with 300 µM glycine and 2 mM hydrogen
peroxide under physiological conditions (37oC and pH 7.6)28. Similar conditions were
reported for the synthesis of oleamide from oleoyl-CoA, except that ammonium chloride
was 125 mM for maximal activity27. Similar experiments were conducted by McCue et
al. demonstrating that arachidonoyl-CoA could also be converted to the fatty glycine by
cyctochrome c29. Ammonium has been implicated as the source of nitrogen in the
amidation reaction producing PFAMs30, however the enzyme responsible for the
conversion was not identified.

Additionally, oleic acid was unable to be converted

directly to either oleoylglycine or oleamide, consistent with the proposed pathway of
Merkler and coworkers24 wherein the fatty-CoA is an essential component in oleamide
biosynthesis.
Bile acid CoA:amino acid N-acyl transferase (BAAT) has also been found to
catalyze the conversion of fatty-CoA substrates to fatty glycines31.

This enzyme

displayed highly variable activity for acyl chain lengths of 16 to 22, and its activity was
markedly decreased when any degree of unsaturation was present.

The relative

enzymatic activity increased for saturated fatty-CoAs of 22 to 26 carbon length. This
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enzyme, therefore, might not aid in the formation of oleamide, but of other long chain
PFAMs.
In 2010, Waluk et al.32 demonstrated that glycine N-acyltransferase-like 2
(GLYATL2) showed specificity with glycine conjugation of fatty-CoAs of medium chain
length (C8 to C18). GLYAT is known to have highest activity with benzoyl-CoA, but is
also capable of conjugating glycine to short chain fatty-CoAs (less than C8)33.
GLYATL2 showed the highest activity with C18:1-CoA (Km = 4 µM) to produce
oleoylglycine. Little to no activity was observed with substrates with fewer than an 8
carbon acyl chain, in the absence of conjugated glycine, and with alanine, serine, or
taurine substituted for the glycine moiety. Additionally, some inhibition was observed
with substrate concentrations above 50 µM. Interestingly, this enzyme was found in the
endoplasmic reticulum localized in the salivary gland, trachea, spinal cord, and skin.
Measurement of levels of NAGs by LC-MS in selected ion mode found highest NAG
levels in the spinal cord and skin34, similar to reports of GLYATL2 localization,
providing evidence that this is a good candidate enzyme for in vivo synthesis. It is
important to note that rodents do not possess the ortholog to hGLYATL2. They do
express the orthologs for hGLYAT and hGLYATL3, however the latter has not yet been
characterized for acyl-glycine conjugating activity.
Several other reports have identified a relatively new pathway for synthesis of
NAGs from NAE precursors. The first report, by Burstein and co-workers35, identified
via radiochromatograms that liver cell extracts produced N-arachidonoylglycine when
anandamide was present. In experiments with RAW 264.7 murine macrophage cells, it
was established that a deuterium labeled anandamide produced a likewise deuterium
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labeled N-arachidonoylglycine as determined with LC-MS/MS studies36. The authors
also demonstrated that incubation of cells with arachidonic acid did not produce Narachidonoylglycine. Application of N-arachidonoylglycine to cell cultures also did not
result in the production of neither arachidonic acid nor anandamide. To support that
alcohol dehydrogenase (ADH) was the enzyme responsible for the conversion of
anandamide to N-arachidonoylglycine; the ethanolamide moiety of anandamide was
deuterium labeled.

Analysis of the products showed deuterium labeling of N-

arachidonoylglycine consistent with the mechanistic actions of ADH. Incubations of
anandamide, glycine,

and recombinant

FAAH were unable to produce N-

arachidonoylglycine, therefore ruling out this enzyme as a participant in the conversion.
These findings have been further supported by in vitro studies of purified ADH
isoforms.

ADH7 was used with anandamide (1-8 M) to determine if this enzyme

catalyzes the production of N-arachidonoylglycine from anandamide37.

Products

analyzed by LC-MS/MS in MRM mode revealed a match to the standard Narachidonoylglycinal.

In incubations of ADH7 with N-arachidonoylglycinal, N-

arachidonoylglycine product was only detected in the presence of enzyme. ADH5 was
found to be inactive for conversion of anandamide to the glycinal or glycine derivative.
However, these studies were conducted under non-physiological conditions.
ADH3 was found to convert NAEs (C2 – C20) to their corresponding Nacylglycinals with Km and Vmax values generally decreasing with increasing chain
length38. These studies were confirmed with analysis by HPLC, GC-MS, and carbon
NMR. Km and Vmax values were unable to be determined for carbon chains above 12 due
to low solubility. However, acetylethanolamine values were V max/Km = 2.7 sec-1M-1, Km
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=
1

450 mM, Vmax = 1.9 µmol/min×mg and lauroylethanolamine were Vmax/Km = 160 sec-

M-1, Km = 0.033 mM, Vmax = 0.14 µmol/min×mg. The fatty-glycinal was found to be

the primary product and conversion to the fatty-glycine was determined to be due to nonenzymatic aldehyde dismutation. Docking experiments indicate the hydroxyl group of the
NAE coordinating with Zn(II) of the active site akin to previously studied ADH3
substrates39,40. The authors suggest that the relatively low Km and Vmax values make it
unlikely that this enzyme plays a significant role during in vivo conversion of NAEs.
The proposed intermediate of oleamide, oleoylglycine, was studied to determine
the physiological effects and the effect on oleamide levels41.

Injection reduced

locomotion and core body temperature. After euthanasia, oleamide levels were found to
not increase in serum, suggesting oleoylglycine has the ability to induce similar
physiological effects as those observed with oleamide. Fatty glycines might not be
requisite intermediates in the metabolic pathway of PFAMs. However, it is still unclear
how this pathway is regulated in vivo.
Thus, current evidence suggests that PFAM synthesis does not proceed directly
from the free fatty acid, but must first be converted to a fatty-CoA substrate for further
modification. The next step in the proposed biosynthetic pathway is controversial, as it is
not known at this time if GLYAT, cytochrome c, BAAT, an unidentfied enzyme, or a
combination is responsible for the conversion to the fatty glycine. If the fatty glycine is
the anabolic intermediate, then conversion to the PFAM has been demonstrated with both
PAM and cytochrome c.

However, the results of Mueller et al.28 suggest that an

alternative pathway, to that proposed by Merkler 22, could also exist leading from the
fatty-CoA directly to the PFAM (see Scheme 1-1 for a pathway summary). It is also
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unclear if glycine, ammonia, or some other molecule may be the source of nitrogen in the
amidation reaction of PFAMs.

For example, addition of glutamine to rat brain

homogenate resulted in modest increase in levels of oleamide30.

Further

studies

are

essential to provide a better understanding of the anabolic pathway for PFAMs, as defects
in their metabolism may contribute to disease states and PFAMS clearly play an
important role in health and fitness.

Scheme 1-1. Proposed pathways of PFAM anabolism suggest a starting product of a fatty acyl
CoA substrate being converted to either to the related N-acyl glycine intermediate or directly to
the PFAM. The substrates shown are of ambiguous length; however note that n (the number of
carbons) does not change according to any of the proposed mechanisms. The enzymes shown
(GLYAT, cytochrome c, PAM, and BAAT) in the conversion of the fatty-CoA to the fatty
glycine or fatty amide are still debated in vivo.

1.2.1. Degradation by Fatty Acid Amide Hydrolase (FAAH)
FAAH activity has been extensively reviewed42-46, and is, therefore, only briefly
discussed. FAAH is a 65 KDa integral membrane protein that enzymatically degrades
fatty acid amides, such as anandamide and oleamide, to their respective fatty acid47,48
(Scheme 1-2). Site directed mutagenesis studies have identified three consensus amino
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acids (K142, S217, and S241 in rFAAH) that are essential for enzyme activity, and these
have been termed the Ser-Ser-Lys catalytic triad49. Rat FAAH has been co-crystallized
with inhibitor methoxy arachidonyl phosphonate and solved to a 2.8 Å resolution50. In
2006, FAAH-2, another enzyme that degrades fatty acid amide substrates, was identified
and has 20% sequence identity with FAAH. FAAH-2 has similar hydrolysis rates with
oleamide (FAAH-1 9.7+/-0.8 and FAAH-2 8.4+/-0.8 nmol/min×mg, respectively) but
could not degrade anandamide as efficiently as FAAH-1 (FAAH-1: 17 +/- 1, and FAAH2: 0.46 +/- 0.04 nmol/min×mg, respectively)51. These two enzymes were found to have
slightly different substrate selectivity, with FAAH-1 preferentially degrading polyunsaturated substrates while FAAH-2 degraded mono-unsaturated substrates. The two
enzymes seem to respond similarly to known inhibitors of FAAH-1 (see references 42-46
for lists of inhibitors). Interestingly, FAAH-2 sequence matches were found in humans
but not in mice or rats, thus care should be taken in direct pharmacological comparisons
across species and subtypes.

Scheme 1-2. Degradation scheme of (A) oleamide and (B) anandamide with enzyme FAAH. The
amide substrates are degraded via hydrolysis to their corresponding fatty acid. For a catabolic
mechanism involving FAAH see references 42 and 45.
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1.3. FATTY ACID AMIDE EFFECTS ON PHYSIOLOGY
The most well-known physiological effect of PFAMs is their sleep inducing
properties. Lerner et al. initially reported the increased concentration of a lipophilic
molecule in the cerebrospinal fluid of sleep deprived cats, which they termed
cerebrodiene16. The structure was later verified as oleamide, and a second component
was identified as erucamide15. Similar studies have also shown an increase in oleamide
in the cerebral spinal fluid in hibernating squirrels 52. Injection of 5 mg/kg of oleamide in
rats induced hypolocomotion and sleep-like behaviors. Other reports have shown that
oleamide injection in mice increases sleep latency and hypomobility11,14,19,53,54.

Oleic

acid and elaidamide (C18:19 trans) did not cause the sleep inducing properties of oleamide,
consistent with specific allosteric interactions of this PFAM with a target receptor. The
sleep induction process was not accompanied with changes in heart rate or blood
pressure, however a concentration dependent decrease in body temperature (2 oC at 20
mg/kg dose) was observed as soon as 30 minutes after injection17,54. The mechanism by
which oleamide acts to induce sleep is currently unknown.
Due to the structural similarity of oleamide and anandamide, other physiological
effects of oleamide related to cannabinoid receptor interaction were investigated. Similar
to the effects of anandamide, oleamide was found to induce overeating in Wistar rats at
all doses tested (0.5-4 mg/kg). It is still uncertain if oleamide is able to interact directly
with cannabinoid receptors in vivo or if the presence of oleamide increases the relative
half-life of anandamide to yield secondary physiological effects.
Erucamide, also found in cerebral spinal fluid with oleamide, was previously
isolated and purified from bovine omentum55.
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This lipid was found to promote

angiogenesis in regenerating skeletal muscle, chick chorioallantoic membrane, rat cornea,
and mouse dorsal air-sac when applied in microgram quantities. Related PFAMs, with
varied acyl chain length, were also tested to determine their ability to promote
angiogenesis. Similar to other reports previously discussed, amides with acyl chains
shorter than 16 carbons showed weak or no angiogenesis, while longer chains approached
activity comparable to erucamide.

The increase in angiogenesis was explored to

determine if this property was an effect of increased cellular proliferation. No increase in
proliferation was observed with erucamide levels < 0.1 mg/mL. These effects were not
affected by addition of glucocorticoid, suggesting that erucamide-induced angiogenesis is
not due to an inflammatory response.

These observations were later replicated by

Mitchell et al. when studying the effect of erucamide on regenerating skeletal muscle 56.
In samples where erucamide seemed to increase angiogenesis in skeletal muscle the
standard deviation was large making interpretation difficult. Additionally, erucamide
application did not change the type of cells present or increase regeneration, consistent
with observations of Wakamatsu et al.55.
NAGs have also been shown to have biological effects similar to PFAMs.
Oleoylglycine has been shown to induce hypothermia and hypomotility in rats to a
comparable potency as oleamide41.

N-arachidonoylglycine has been demonstrated to

dose dependently attenuate T lymphocyte proliferation35. This substrate was also found
to reduce IL-1β secretion from human peripheral blood mononuclear cells with treatment
at 1 and 10 µM. Additionally, 0.43 µg palmitoylglycine administered via intradermal
injection suppressed the response to heat stimulus at 45-52oC57 and 275 nmol of Narachidonoylglycine reduced formalin-induced pain response. In the following sections
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we focus on the observed effects of PFAMs and NAGs on metabotropic and ionotropic
receptors, transporters, and gap junction proteins. These results are also summarized in
Table 1-2.
Target

Substrate

5-HT1AR
5-HT2AR
5-HT2CR
5-HT3R
5-HT7R

Oleamide
Oleamide
Oleamide
Oleamide
Oleamide

CB1R

Oleamide

GABAA R

Effect
Potentiates
Potentiates
Potentiates
No effect
Inhibits
No effect
Potentiates
No effect
Potentiates
(α1β1γ2s)
Potentiates
(α1β2γ2L)
Potentiates
Potentiates
Inhibits

Oleamide

Maximal
Response
100 nM
100 nM
100 nM
100 nM
-

EC50
10 µM*

500 nM
28 µM

Reference
3
3, 7
5, 3
5
7
13
12
5
66
64

15 µM
10
α1 GlyR
Oleamide
22 µM
64
Gap
100 µM
50 µM
71
Oleamide
Junction
GLYT2a
Arachidonoylglycine Inhibits
5.1 µM*
67
GLYT1b
Arachidonoylglycine No effect
67
GAT1
Arachidonoylglycine No effect
67
TRPV1
Anandamide
Potentiates
5-12 µM 73, 77
Table 1-2. Summary of effects of oleamide, N-arachidonoylglycine, and anandamide
on various receptors, transporters, and gap junction proteins. The * denotes values
reported as an IC50.
Orphan receptors were excluded due to incomplete
characterization at present time.
1.3.1. Serotonin Receptors
After the discovery that oleamide accumulates in the cerebral spinal fluid of sleep
deprived mammals15,16 many reports were published on the effect of oleamide on
serotonin (5-hydroxytryptamine) receptors (5HTRs), due to the link between 5-HTR
activity and sleep58-60.

c-Fos, a protein that regulates transcription, is found to be

upregulated in specific brain regions of rat during night hours7. Intraperitoneal injections
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of oleamide administered to rats induced a normal sleep-like state during daytime hours.
Immunohistochemical staining and in situ hybridization indicated that c-Fos expression
was increased in rat brain 45 minutes to 2 hours after injection with oleamide 7.
Expression of 5-HT7R was identified in the same regions as c-Fos upregulation. The
most prevalent areas of c-Fos upregulation as a result of oleamide treatment were the
cerebral cortex, hypothalamus, and thalamus. Injections of oleic acid increased c-Fos
expression as well; however the increase was not as significant as that observed with
oleamide.
Huidobro-Toro et al. reported the effects of oleamide on Xenopus oocytes
expressing either 5HT2AR or 5HT2CR by observing chloride currents produced by
downstream signaling via two electrode recordings. Oleamide reversibly potentiated
both serotonin subtypes via altered efficacy of 5HT 2AR and reduction of the EC50 of
5HT2CR. Co-treatment of the oocytes with kainate or carbachol, competitive inhibitors of
5HTR, did not alter the effects of oleamide suggesting oleamide acts at an allosteric site.
Changing the cis- double bond to a trans- configuration, altering the head group to a
carboxylic acid from the carboxamide, or movement of the double bond eliminates the
potentiation effect observed with oleamide (stearamide (C18:0) exhibits inhibitory
effects).
Boger et al. reported maximal potentiation of subtypes 5HT 1AR and 5HT2AR
when 100 nM oleamide was co-administered with 5HT3. Receptor activity was measured
by calorimetric assay for β-galactosidase in NIH 3T3 cells expressing 5-HT2AR, or in
RAT-1 cells expressing 5-HT1AR and the β-galactosidase gene. Of the lipid variants
tested, oleamide was found to have the highest activity.
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Patterns in activity were

discerned by systematic alternation of oleamide’s structure, as compounds containing an
olefin at a Δ9 from the methyl terminus showed small potentiation while compounds with
the olefin at Δ9 from the head group position were inactive. Movement of the double
bond further from the carboxamide produced inactive compounds, while positioning the
double bond closer to the carboxamide resulted in inhibitory effects. An overall increase
in unsaturation points typically decreased potentiation. These results were mimicked in
both receptor subtypes, however, 1A receptor subtypes were more tolerant of structural
changes to oleamide than 2A receptor subtypes.
Oleamide was also found to increase phosphoinositide hydrolysis in 5HT 2AR
when co-administered with 5HT6.

As in previous reports, in the absence of 5HT

oleamide had no substantial effect on phosphoinositide hydrolysis and increased cAMP
accumulation. However, oleamide induced inhibition of cAMP in the presence of high
concentrations of 5-HT (1 mM). Oleamide was shown to inhibit cAMP accumulation and
radiolabeled 5-HT binding to 5HT7R in a concentration-dependent manner6,8. Clozapine,
a high affinity inhibitor of 5-HT7R, was unable to block the increase in cAMP in response
to oleamide treatment. It was, thus, concluded that oleamide acts at an allosteric site,
which is in agreement with the results previously discussed 4.

1.3.2. Cannabinoid Receptors
Because PFAMs are structurally similar to the N-acylethanolamine (NAE) fatty
acyl subclass, such as the endocannabinoid anandamide, efforts have been made to
determine if oleamide is an endogenous ligand for cannabinoid (CB) receptors. Reports
on oleamide interaction with CB1 receptors have provided conflicting results thus far.
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Oleamide causes concentration-dependent vasorelaxation of rat mesenteric resistance
arteries9,61,62. In the presence of AM251, a CB1 receptor subtype inhibitor, but not
AM630, a CB2 subtype receptor inhibitor, the vasorelaxation was attenuated, suggesting
that oleamide may induce these effects partially through action of CB 1 receptors9. These
effects were also reduced in the presence of O-1918, an inhibitor of the non-CB1/CB2
receptor, and with inhibitors of the vanilloid receptor 1 (TRPV1). The attenuation was
not observed in the presence of CB1 receptor inhibitor when the mesenteric arteries were
denuded of endothelium. The vasorelaxation effect was also reduced in the presence of
nitric oxide synthase inhibitor, L-NAME, and with K+ and Ca+ channel inhibitors,
indicating that oleamide may have several modes of action with respect to
vasorelaxation9,62. Addition of a fatty acid amide hydrolase inhibitor had no effect on the
ability of oleamide to induce vasorelaxation9.

Since formation of the catabolic

metabolite, oleic acid, is inhibited in these studies it is concluded that carboxamide
functionality is necessary for the vasorelaxation response. As expected from the FAAH
study, exogenous application of oleic acid to rat mesenteric resistance arteries had no
observable effect 9. Several other reports have shown low affinity (IC 50 10 µM12) or
negligible binding of oleamide to CB1 receptor13. It is unclear if solubility is contributing
to the conflicting results, as some samples are prepared in an organic solvent-containing
solution while others dissolved the lipid agent in saline. However, the physiological
concentration of oleamide and other PFAMs in mesenteric arteries or heart, as well as
other organ systems, is not reported. Interestingly, PAM activity was found to be 1000
times higher is the atrium, while no amidated peptides have been reported in that region.
Since PAM is the proposed anabolic enzyme for PFAMs it is possible that PFAM levels
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in heart may be higher than previously reported in cerebral spinal fluid or plasma (nM).
Knowledge of these levels will aide in determining if PFAMs are endogenous
endocannabinoids that can invoke signaling in vasorelaxation pathways. Additionally,
this information may provide insight to other physiological roles as well as their
anabolism in vivo.

1.3.3. GABA and Glycine Receptors
Oleamide administration via intraperitoneal injection in mice shows analgesic-like
effects19 and, as previously stated, is shown to increase in the cerebral spinal fluid of
animals subjected to 6 or more hours of sleep deprivation15. GABA receptors (GABAR)
are targets for various sedatives, such as barbiturates and anesthetic steroids63, raising
speculation that oleamide may well interact with GABARs. In GABA AR β3 subunit
knockout mice, intraperitoneal injection of oleamide (0.8 mg/kg or 1.6 mg/kg) did not
produce a decrease in sleep latency that is typically observed in wild type mice treated
with oleamide as compared to wild-type controls11. Additionally, no other hypnotic
effects were observed in the knockout mice versus controls not injected with oleamide.
Therefore, it seems that GABAR may play a role in the oleamide-induced signaling
pathway that causes sleep. Other reports have also shown that oleamide’s effects may be
subunit-dependent.

Electrophysiological measurements have shown that oleamide

potentiates chloride currents in α1β1γ2 or α1β2γ2 GABARs with an EC 50 of
approximately 20 µM10,64-66. Oleamide alone had no effect on current as compared to
controls, and current enhancement was not observed with the α1β2 receptor type 10.
Radiolabeled binding assays indicated that binding of GABA was not affected by
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oleamide application19,64. The EC50 for GABA was reduced, while the Hill slope was
unaffected by exogenous application of oleamide, suggesting that oleamide works
through an allosteric-type mechanism64. Oleamide was found to potentiate α1 glycine
receptor homopentamers, with a similar EC50 to GABAR, but overall current
enhancement was less marked than with GABARs. It has been suggested that receptor
potentiation could be affected by second messenger signaling or altered receptor
phosphorylation53.

Such changes in phosphorylation have been observed in α1

connexins67 (see 3.5 Gap Junctions and Ca2+ Signaling). However, these possibilities
are unexplored for GABARs and GlyRs.

1.3.4. Glycine Transporters
In studies of the glycine transporter 2a (GLYT2a), co-application of glycine (30
uM) and N-arachidonoylglycine (10 µM) to Xenopus oocytes reduced the amplitude of
the glycine mediated current measured by two electrode voltage clamp 68,69. Washout of
N-arachidonoylglycine and subsequent application of glycine produced current levels
similar to those observed before exposure to N-arachidonoylglycine. No difference in
current amplitude was observed with treatment with staurosporine, thus, the observed
inhibition by N-arachidonoylglycine is not linked to protein kinase C activation. In
addition, N-arachidonoylglycine treatment also reduced the amount of glycine uptake.
Given these observations, it was concluded that reduction in glycine currents was a result
of N-arachidonoylglycine inhibition of GLYT2a activity. Concentration response data
for glycine in the presence and absence of 10 µM N-arachidonoylglycine revealed that
the substrate acts as a reversible, non-competitive inhibitor with an IC50 = 5.1 ± 3.1 µM.
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Similar experiments show that N-arachidonoylglycine is not a substrate for GAT1 and
GLYT1b.

1.3.5. Gap Junctions and Ca2+ Signaling
Oleamide, and another structurally similar PFAM, linoleamide (C18:2 9,12), were
studied to determine their effect on gap junction communication and Ca 2+ signaling.
Application of 50 µM oleamide abolished gap junction transfer of Lucifer Yellow dye
and conductance in cultured rat glial cells67,70. Oleic acid and elaidamide (C18:19 trans)
had no effect on dye transfer, nor conductance, even at concentrations greater than 50
µM. Other structural analogs, such as cis-8-octadecenamide, cis-11-octadecenamide, or
the ethanolamine derivative, were effective at blocking gap junction communication, but
with less potency than oleamide67. Subsequent studies using a broad range of analogs
found that the cis-9 olefin position and stereochemistry determined the magnitude of
PFAM effect on gap junction activity in glial cells70.

Moving the double bond “up or

down” the chain, as well as changing the stereochemistry from cis- to trans-, reduced the
observed inhibition of gap junctions. Erucamide (C22:1 13), a natural PFAM containing
the typical positional isomer of C22:1, had negligible inhibitory effects, while a synthetic
derivative, cis-9-docosenamide (C22:19), inhibited gap junction activity to levels
comparable to oleamide. Variations in the acyl tail length were tolerable within a narrow
range (C16 to C20). Shortening the acyl tail length to C14 reduced the inhibitory effect,
while acyl tails longer than C20 also showed diminished inhibition. All of the polyunsaturated fatty acids studied were less potent than oleamide, with the exception of
arachidonamide (C20:48,11,14,
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) which showed 90-100% inhibition at 20-100 µM70.
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Some tolerance was observed when the head group of oleaminde was altered. The ethyl
ester and a sarcosine derivative retained a portion of activity, but the NAG, oleoylglycine
(a suspected anabolic precursor to oleamide), did not inhibit gap junction communication.
This data supports the hypothesis that amidation of these species confers biological
activity. Other derivatives also retained similar inhibitory properties with respect to gap
junctions if the structural alterations contained a π-electron system at the Δ9 position
and/or were perturbed such that the molecule adopted a “hairpin” configuration70.
Calcium signaling can traffic through gap junctions, therefore calcium wave
propagation was investigated in rat glial cells treated with oleamide, a gap junction
inhibitor67. Oleamide and anandamide were found to have no effect on calcium wave
propagation, suggesting that gap junction inhibition is not caused by molecular
“blocking” or insertion into the junction.

Oleamide was found to block gap junction

communication of cells with α1 and β1 connexin similarly, while oleic acid and
elaidamide (C18:19 trans) had no effect. Since α1 connexin may be either non-, mono- or
di-phosphorylated, changes in phosphorylation were tested in response to oleamide
pretreatment. In cells exposed to oleamide, there was a significant decrease in the diphosphorylated isoform.

After washing the cells to remove oleamide, the di-

phosphorylated isoform returned to basal levels. To our knowledge this is the sole report
of PFAMs altering protein phosphorylation.
50 µM oleamide caused an increase in internal calcium of T24 and BFTC bladder
cancer cells, human MG63 osteoblast-like cells, canine MDCK renal tubular cells and rat
PC12 pheochromocytoma cells71. T24 cells had the largest oleamide-induced internal
calcium increase of these cell lines. The effect was concentration dependent between 10-
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100 µM with an EC50 of 50 µM. Linoleamide, a congener of oleamide, was found to be
more potent, with an EC50 of 30 µM. The source of internal calcium increase was found
to be mainly from influx, as determined by removing external calcium71,72. However, this
concentration increase was found to be partially due to release of endoplasmic reticulum
stores, as cell pretreatment with thapsigargin, an endoplasmic reticulum pump inhibitor,
blocked the oleamide or linoleamide-elicited effect.
Palmitoylglycine treatment (10 µM) of F-11 cells was found to increase calcium
influx (EC50 = 5.5 µM) as measured by fluorescence with the calcium fluorophore, Fura257. Stearoylglycine and stearic acid were found to marginally elevate calcium influx.
Other

related

fatty

glycines

such

as,

oleoylglycine,

N-arachidonoylgylcine,

docosahexaenoylglycine, as well as free glycine were unable to affect calcium levels at
concentrations up to 50 µM. 10 µM of ruthenium red and 1 mM La3+, abolished calcium
response due to palmitoylglycine treatment and pertussis toxin attenuated the effect. 2
µM treatment with ω-conotoxin MVIIC or ω-conotoxin GVIA, voltage-gated calcium
blockers, did not affect the influx of calcium.

1.3.6. Transient Receptor Potential Vanilloid Receptors
Transient receptor potential (TRP) cation channels are key receptors in the
perception of pain and are activated by noxious stimuli including heat, cold, pH, and
lipidergic substances. Here we will discuss briefly their interaction with various N-acyl
ethanolamines and N-acyl amino acid derivatives. For a more complete picture of TRP
receptors, please see the following reviews73-76.
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Anandamide (C20:4 NAE) was found to induce vasodilation in rat hepatic and
small mesenteric arteries and guinea-pig basilar artery, as well as increase calcitonin
gene-related peptide (CGRP) and increase tissue content of cAMP in rat hepatic artery 77.
Pretreatment with capsaicin and 8-37 CGRP (vasodilator neuropeptide anatagonist)
abolished anandamide induced relaxation and capsazepine (vanilloid receptor
anatagonist), inhibits vasodiliation and attenuates release of CGRP. These effects were
shown to be TRPV specific, as SR141716A (CB1 receptor antagonist), ω-conotoxin
GVIA, MVIIC, nor nimodipine (voltage-gated calcium blockers) did not block
anandamide induced relaxation. 2-arachidonylglyercol and palmitylethanolamide were
unable to elicit a response. Similar activity with other NAEs on TRPV has been reported.
Linolenoylethanolamine

(C18:3),

linoleoylethanolamine

(C18:2),

and

oleoylethanolamine (C18:1) were found to induce concentration dependent vasodilation
in rat mesenteric artery, which was blocked by capsazepine and arteries pretreated with
capsaicin78. The observed relaxation of arteries treated with oleoylethanolamine was
nearly

absent

in

TRPV1

linoleoylethanolamine,

knockout

oleoylethanolamine,

mice.

Linolenoylethanolamine,
anandamide,

and

N-

Docosatetraenylethanolamine (C22:4) dose-dependently increased intracellular calcium.
LC-MS/MS

experiments

revealed

that

stearoylethanolamine

(C18:0),

oleoylethanolamine, and linoleoylethanolamine were found in higher levels in mesenteric
arteries compared to anandamide (21, 16, and 19 pmol/mg protein respectively), however
activity in calcium assays required at least one unsaturation point.
While the above experiments with NAEs required low micromolar quantities,
some N-acyl dopamines were found to have a much higher potency. N-arachidonoyl
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dopamine was found to increase intracellular calcium in HEK293 cells overexpressing
hVR1 (EC50 = 40 nM) and rVR1 (EC50 = 48 nM)79. This increase was abolished by
iodoresiniferatoxin. Intradermal injection of N-arachidonoyl dopamine (1.5 µg) in the
hind paw of Sprague-Dawley rats resulted in thermal hyperalgesia. Analysis via MS
showed the highest concentrations of N-arachidonoyl dopamine in the striatum,
hippocampus, and cerebellum.

Similar experiments were conducted with N-oleoyl

dopamine, N-palmitoyl dopamine (C16:0), and N-stearoyl dopamine (C18:0)80.

In

agreement with previous trends, the saturated compounds, N-pamitoyl dopamine and Nstearoyl dopamine, were found to be inactive in calcium mobilization and thermal
hyperalgesia assays. N-oleoyl dopamine increased calcium mobilization (EC50 = 36 nM)
and thermal hyperalgesia (EC50 = 0.72 µg) with a somewhat greater potency than Narachidonoyl dopamine.
Recently Bradshaw and colleagues have reported striking similarities between the
activity profiles of palmitoylglycine, an NAG, and TRPC5 and this hypothesis is
currently under investigation by their group74. Though not data currently exists for
activation of TRP receptors and NAGs or PFAMs, the striking similarity of these lipid
subclasses and the above lipidergic ligands makes it intriguing to speculate that these
compounds may, too, be endogenous activators.

1.3.7. Interaction with Orphan G-protein Coupled Receptors
Recently there has been an effort to identify and match orphan receptors to
physiologically relevant ligands.

GPR92 is an orphan receptor that is part of the

rhodopsin-like GPCR family. It has been shown by reversed transcription PCR to have
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the highest mRNA levels in dorsal root ganglia in the nervous system, spleen, stomach,
intestine, thymus, and kidney69,81,82.

As previously mentioned, N-arachidonoylglycine

shows similar distribution levels as GPR9234.

In studies of CV-1 cells, addition of N-

arachidonoylglycine increased levels of inositol phosphate in a concentration dependent
manner, with an EC50 > 50 µM as measured in radioactivity assays81. This increased
inositol phosphate production was abolished by treatment with a phospholipase C
inhibitor, U73122.

Additionally, N-arachidonoylglycine caused a dose-dependent

increase in intracellular calcium concentration that was not blocked by treatment with
pertussis toxin, as measured in DRG neurons. N-arachidonoylglycine was not, however,
able to affect levels of cAMP.

Molecular modeling and site-directed mutagenesis

identified residues Thr97, Gly98, and Phe101 on transmembrane domain 3 of GPR92 as
interacting with N-arachidonoylglycine.
N-arachidionoylglycine was also found to interact with GPR18, an orphan
receptor expressed in T and B cells69,83. Treatment with 10 µM N-arachidionoylglycine
increased intracellular calcium release in L929 cells, and this effect was also observed in
K562 and CHO cells with a 2 to 3 fold higher response83. Unlike GPR92, treatment of
cells expressing GPR18 with 100 nM N-arachidonoylglycine had a 70% inhibition of
cAMP production (IC50 = 20 nM).

However, other groups using techniques like

PathHunter assays and electrophysiology have disputed N-arachidonoylglycine activation
of GPR1884,85.
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1.4. ANALYSES METHODS
PFAMs and NAGs have shown a wide variety of physiological effects on receptor
activity and animal behavior. However, it is often difficult to analyze the content and
identity of these bioactive lipids.

PFAMs are generally found at nM levels at

physiological levels and absorb very weakly in the UV-Visible region making detection
and identification using conventional methods challenging. Additionally, NAGs have
been reported in ranges of pmol of amide per gram of tissue analyzed. In the following
sections we review methods for the isolation, separation, and detection of PFAMs and
NAGs from biological samples.

1.4.1. Chromatographic Separation Techniques
Sample preparation, in terms of extraction and/or isolation of PFAMs, is the
preceding step in any chromatographic separation technique.

This step can be

challenging, as many of the fatty acyl subclasses share similar properties with PFAMs.
The most common extraction for PFAMs is a Folch-Pi extraction86, which isolates the
fatty acyls, triacylglycerols (TAGs), diacylglycerols (DAGs), monoacylglycerols
(MAGs), N-acyl glycines (NAGs), PFAMs, and N-acylethanolamines (NAEs).

A

toluene:acetone (4:2) solvent mixture was used to extract erucamide from various organ
tissue87. Extraction is sometimes accompanied by an isolation step, typically utilizing
solid phase extraction (SPE) methods88-90. An SPE method for isolation of only PFAMs
from standard lipid mixture and N18TG2 mouse neuroblastoma cells was detailed by
Sultana et al.89

PFAM recoveries were 70% or greater for 0.2-20 µg of amide loaded

onto the SPE columns and fractional lipid content was verified by TLC. This method
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could be used for isolation of any of the nine lipid subclasses (fatty acids, PFAMs, NAG,
NAE, MAG, DAG, TAG, cholesterol, and cholesterol esters) tested. Likewise, the TLC
method outlined could be employed for qualitative composition studies.
Gas chromatography has been used to identify PFAMs isolated from luteal phase
plasma2, N18TG2 mouse neuroblastoma cells20,89, oleamide in plasma and cerebral spinal
fluid21, and erucamide in pig organs and blood87. All of the listed analyses employed a
5HP-MS capillary column for separation.

The temperature elution profile differed

slightly if the sample was trimethylsilyl derivatized or analyzed as the native structure.
An alternative column, BPX-70, was able to resolve 6 C18:1 PFAM trimethylsilyl
stereoisomers89. The trans isomers eluted at least a minute prior to their corresponding
cis isomers. Additionally, the retention time was found to increase as the double bond
position was closer to the carbonyl group. The elution trends observed could aide in
identification of stereoisomers even if mass spectrometry detection is not available.
Liquid chromatography is a viable alternative to gas chromatography, especially
with the recent increases in column technology. Reversed phase C18 stationary phases
are the most common choice for separation of PFAMs20,25,55. However, if resolution of
short chain amides (C2-C12) are desired a C8 column can be employed25. Separation is
typically achieved by gradient elution with acetonitrile/water or methanol/water solvent
mixtures.

Gradient elution programs vary depending on the resolution of analytes

desired, the column properties and experimental details are provided in the cited
publications. These methods were used to purify erucamide from biological samples 87,
PFAM content in tallow90, and to examine PFAM content and anabolism in N18TG2
mouse neuroblastoma cells20.
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For separation of NAEs and NAGs, Burstein et al. employed silica gel TLC of
radiolabeled NAE and NAG substrates35. Separation was achieved by a chloroform,
methanol, acetic acid mixture and retention visualization was accomplished by
scintillation counting.

Separation of NAGs from complex mixtures has been

accomplished by primarily C18 reversed phase chromatography with water and
acetonitrile or methanol gradients34,57,91. Tissue studies were carried out in rat tissue and
bovine brain34,57.

1.4.2. Detection Methods
UV-Visible spectroscopy and mass spectroscopy (MS) detection methods were
utilized in conjunction with the above separations.

Carpenter et al. used liquid

chromatography with UV detection at 210 nm to assess PAM mediated changes in PFAM
levels of mouse neuroblastoma cells25. Because PFAMs do not absorb UV light readily,
the limit of detection (100 µM) for this method was relatively high. At this limit of
detection, trace analysis is not possible unless a large amount of sample is processed and
concentrated. However, this method is useful, as an LC with a UV-Vis detector is
ubiquitous in most institutions. Other analysis systems for PFAM detection typically use
a mass spectrometer because it is compatible with gas or liquid chromatography.
Additionally, modes such as selected ion monitoring, or multiple reaction monitoring
(MRM) in tandem mass spectrometers, can allow for lower detection limits, enabling
trace analysis92.

When using electron ionization, as found in gas chromatography

instruments, the fragmentation pattern can be matched to standard databases for
component identification.

If PFAM fragmentation patterns are not provided in the
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database software, reports have been published of electron ionization fragmentation
assignment of PFAM-TMS derivatives93 or post-column mass spectra of collision
induced dissociation of PFAMs94. PFAM content in tallow was investigated by liquid
chromatography atmospheric pressure chemical ionization mass spectrometry with a
reported limit of detection of 18.5 femtomoles90.
Detection methods for NAGs have primarily been published on MS or tandem
MS. For quantitation studies of bovine brain and rat tissue LC/MS and calibration curves
were used to determine levels of NAGs34.

This study ranged from value of

approximately 2 to 140 pmol per gram of dry tissue.

Rimmerman et al. obtained

quantitation of palmitoylglycine and N-arachidonoylglycine in Sprague-Dawley rat brain
utilizing LC and tandem MS with a triple quadrupole operated in MRM mode57.
Quantitation levels were between 6 and 895 pmol per gram of tissue. Both reports
demonstrate identification of NAGs in mixtures using accurate mass quadrupole time of
flight mass spectrometers34,57.

1.5. SUMMARY AND OUTLOOK
The knowledge gained on the metabolism and physiological interaction of
PFAMs and biological systems has grown significantly since these molecules were first
reported in 1989.

The degradation of these lipid messengers by FAAH is well

characterized, however there are still ample questions pertaining to their anabolism in
vivo. The enzymes responsible for conversion of the fatty-CoA to the primary amide are
still largely debated. Additionally, there is still not a clear picture of how these molecules
are regulated in signaling, whether systemically or locally within specific tissue regions.
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Intraperitoneal injection of oleamide in mice causes a sleep-like state characterized by
hypomotility, hypothermia, and ptosis that are not blocked by treatment with a CB1
antagonist95. Therefore, oleamide seems to exert physiological signaling effects that are
independent of anandamide and the cannabinoid system.

Exogenous application of

oleamide to the serotonin and GABA receptor systems indicated that physiological
effects may be modulated by receptor interaction as deletion of the β3 subunit of the
GABA receptor abolished the hypnotic effects observed with oleamide treatment 11.
Interestingly, differential phosphorylation was observed in the cellular connexin protein
with exogenous application of oleamide in gap junction studies67. Therefore, PFAMs may
modulate receptor function via downstream signaling or by changing phosphorylation
states, although no further studies have been conducted. Nonetheless, PFAMs are an
emerging class of bioactive signaling molecules whose wide range of modulatory
activities are only recently becoming discovered. It is critical that the anabolic and
signaling pathways for these physiologically-important effectors be elucidated. This
knowledge may provide invaluable insight to disease states or provide pharmacological
strategies and novel therapeutics for a wide-range of symptoms, such as in treatment of
pain and inflammation44.
There are established isolation procedures and relatively predictive elution
profiles of this class of lipids due to their structural similarity with fatty acids. Future
analyses of these classes of lipids will benefit from the rise in sophistication of column
and mass spectrometry technology. UPLC and nano-HPLC are advantageous as they
reduce band broadening and total analysis time, providing analysis that is fast and of
increased sensitivity. Chipcube LC systems are available with an option of trapping
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columns, thus, having the potential to increase sample load while reducing a portion of
the matrix contaminants which can cause ion suppression in MS.

Our laboratory,

amongst others, is also currently investigating microfluidics and laser induced
fluorescence platforms to aid in reducing sample requirements and increasing detection
sensitivity.

Initial findings indicate detection limits below those achievable by MS

(unpublished work). PFAMs and NAGs, unfortunately, are not currently represented in
LIPID Metabolites and Pathways Strategy (LIPID MAPS) 96, and MetLIN databases.
However, several select PFAMs and NAGs are available in the Human Metabolome
Database (HMDB).

Current efforts to determine anabolic pathways, receptor-ligand

interaction studies, and new quantitative analysis in biological samples leaves the field
poised for advancement in broadening our knowledge of the effects of PFAMs in vivo.
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Chapter 2

Electrospray Ionization and Collision Induced
Dissociation Mass Spectrometry of Primary Fatty
Acid Amides and N-acyl Glycines
Adapted from: Divito, E. B., A. P. Davic, et al. (2012). "Electrospray ionization and
collision induced dissociation mass spectrometry of primary fatty acid amides."
Analytical chemistry 84(5): 2388-2394.
2.1. ABSTRACT
Primary fatty acid amides are a group of bioactive lipids that have been linked
with a variety of biological processes such as sleep regulation and modulation of
monoaminergic systems. As novel forms of these molecules continue to be discovered,
more emphasis will be placed on selective, trace detection. Prior to this report, there was
no published experimental determination of collision induced dissociation of PFAMs. A
select group of PFAM standards, 12 to 22 length carbon chains, were directly infused into
an electrospray ionization source Quadrupole Time of Flight Mass Spectrometer. All
standards were monitored in positive mode using the [M+H]+ peak.

Mass Hunter

Qualitative Analysis software was used to calculate empirical formulas of the product
ions.

All PFAMs showed losses of 14 m/z indicative of an acyl chain, while the

monounsaturated group displayed neutral losses corresponding to H2O and NH3. The
resulting spectra were used to propose fragmentation mechanisms. Isotopically labeled
PFAMs were used to validate the proposed mechanisms. Patterns of saturated versus
unsaturated standards were distinctive, allowing for simple differentiation.

This

determination will allow for fast, qualitative identification of PFAMs. Additionally, it
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will provide a method development tool for selection of unique product ions when
analyzed in multiple reaction monitoring mode.

2.2 INTRODUCTION
Primary fatty acid amides (PFAMs) are a subclass of fatty acyls containing a
carboxamide head group and an acyl tail of varying carbon length and unsaturation. This
group of lipids contains endogenous biomolecules, many of whose exact physiological
role has not been identified.

Although distinct metabolic pathways have yet to be

elucidated for this class of biomolecules, they have been located in several specific
tissues and biological fluids since the late 1980s. The first reported discovery of PFAMs
was of palmitamide (hexadecanoamide, denoted C16:0), oleamide (C18:1 9) and
linoleamide (C18:29, 12) in luteal phase plasma.2 Oleamide and erucamide (C22:113) were
subsequently identified in the cerebral spinal fluid of sleep-deprived cats.15,16
Exogenous application of oleamide was shown to potentiate serotonin receptor subtypes
1A, 2A, and 2C, as well as to potentiate the class A type of ɣ-aminobutyric acid receptor,
GABAAR.3-6,10 Oleamide has also been found to inhibit gap junction communication
when exogenously applied to glial cells.67,70 This lipid was reported to induce various
physiological properties such as vasorelaxation, increased food uptake, anti-anxiety, and
analgesic-like properties.9,14,17,18,62

While less well characterized than oleamide, the

physiological properties of other PFAMs have been reported. For example, erucamide
promotes angiogenesis and regulates water balance56,87, and linoleamide induces sleep
and increases cytosolic calcium levels in renal tubular cells.72 These effects have been
ascribed to the carboxamide head group since the free fatty acid form does not produce,
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or greatly reduces, the observed effects. There is also selectivity shown for the double
bond position and acyl chain length.
PFAMs exhibit a broad range of physiological effects and, therefore, may be
bioindicators for disease states. However this lipid class is typically found at low
concentrations. Investigation of the levels of these amides in biological fluids and tissues
suggests that physiological concentrations are in the nM range. 2,16,20,21

This makes

separation and detection of physiological levels of PFAMs challenging. Much of the
separation and detection work to date has been conducted on the N-acylethanolamine,
anandamide, though a few reports exist on other PFAMs. Separation of PFAMs has
involved mainly gas chromatography (GC) and high performance liquid chromatography
(HPLC) with either the endogenous species or a derivatized form as the analyte. PFAMs
were analyzed in plasma2, cerebral spinal fluid15, and mouse neuroblastoma cells20,89 by
derivatization to trimethylsilylamides, followed by GC separation with mass
spectrometry (MS). HPLC is an alternative to GC for separation of PFAMs since it does
not require derivatization if a MS detector is used.

HPLC-MS has been used to

investigate the conversion of N-acylglycines to PFAMs in vitro25.
In order to examine the presence and levels of PFAMs in biological samples it is
necessary to first extract these lipids from the sample. Folch-Pi or Bligh-Dryer extraction
techniques are common; however these methods may co-extract other subclasses of fatty
acyls such as fatty acids, N-acylethanolamines, and N-acylglycines.89 In addition, many
of the fatty acyls are isobaric, further complicating the analyses. This makes front-end
separation a necessity as many of the isobars can be resolved solely by chromatography.
Additionally, tandem MS is becoming a prevalent tool for selective, sensitive detection of

33

lipids.

The sensitivity has been reported as femtomoles in optimized systems. 97,98

Additionally, no sample derivativation is needed in an LC-MSMS system, making it
attractive for lipid analysis.
Some fatty amide fragmentation mechanisms have been investigated with
electron ionization or collision induced dissociation. 93,99 There are a few reports on
endogenous PFAMs where tandem MS was utilized for structural identification. 15,100,101
In order to enhance the selectivity and sensitivity of tandem MS using multiple reaction
monitoring (MRM), knowledge of the fragmentation mechanism must be known. This is
especially true when investigating the fatty acyl group as all of the subclasses will contain
acyl chain fragments in CID spectra. It is, therefore, important to identify product ions
that are unique to the fatty acyl subclass so that the selectivity and sensitivity of MRM
can be utilized. In order to provide essential tools to allow for identification of these
physiologically relevant class of lipids, we report proposed fragmentation mechanisms of
various saturated and mono-unsaturated PFAMs based on the observed product ions
obtained with a quadrupole time of flight (QToF) MS.

2.3. MATERIALS AND METHODS
2.3.1 Chemicals:
Methanol optima grade and ammonium hydroxide were purchased from Fisher
Scientific (Fair Lawn, NJ, USA). Oxalyl chloride,

13

C2-9,10-oleic acid, oleic acid, erucic

acid, petroselaidic acid, and anhydrous dichloromethane were from Sigma Aldrich (St
Louis, MO, USA). N, N-dimethylformamide,

13

C-1-hexadecanoic acid, heptadecanoic

acid, and eicosanoic acid were purchased from Aldrich Chemical Company (Milwaukee,
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WI, USA).

Lauric acid, myristic acid, palmitic acid, stearic acid, formic acid, and

docosanoic acid were purchased from Acros Organics (New Jersey, USA). Elaidic acid
was from MP Biomedical Inc. (Solon, OH, USA) and linoleamide was purchased from
Enzo Life Sciences (Ann Arbor, MI, USA). Oleoylglycine was purchased from Cayman
Chemicals (Ann Arbor, MI, USA).

2.3.2 PFAM synthesis:
PFAMs were synthesized by a modified procedure described by Philbrook. 102
Fatty acids were dissolved in anhydrous dichloromethane and converted to the acid
chloride by reaction with oxalyl chloride under anhydrous argon atmosphere.
Dichloromethane solvent was removed by rotary evaporation in vacuo, and the remaining
acid chloride was subjected to ammonia gas by insertion of ammonium hydroxide filled
syringes. Reactions were complete when the fatty acid chloride oil was completely
converted to a white solid fatty acid amide product. Products were purified by liquid
phase extraction with chloroform.
Purity of all synthesized amides was verified by GCMS on a Varian CP-3800 GC
with Varian Saturn 2000 Ion Trap Mass Spectrometer.

Gas chromatography was

performed on a Varian Factor Four Capillary Column (VF-5ms, 30 m × 0.25 mm ID)
with a flow of 1 mL/min helium carrier gas. Injector temperature was held at 250 oC with
split injection (ratio 10). Temperature gradient started at 55 oC and ramped 40oC/min to
150oC with a hold of 3.62 minutes before ramping 10oC/min to 275oC and holding 6.50
minutes. The total run time was 25 minutes. Eluted fatty amides were ionized by
chemical ionization with methanol and analyzed in selected ion mode. The peak area of

35

fatty acid substrate and PFAM product from GC-MS runs were used to determine purity.
All PFAMs were found to be of 98% purity or greater.

2.3.3 Mass spectrometry:
PFAM fragmentation patterns were obtained on an Agilent Technologies 6530
Accurate Mass QToF LCMS with electrospray ionization source. Samples of 10 µM of
amide in 95:5 methanol/water solvent with 0.3% formic acid (v/v) were introduced by
direct infusion at 500 µL/min using a Harvard Apparatus 11 Plus syringe pump. Mass
spectral parameters were as follows: gas temperature 300 oC, drying gas 8 L, nebulizer
pressure 35 psi, sheath gas temperature 350oC, sheath gas flow 11 L, capillary voltage
4000 V, fragmentor voltage 150 V, nitrogen collision gas, and collision energy 20-35 mV
depending on sample identity. Each sample was infused and spectra collected for 1
minute, with a final average of 20 scans/spectra.

Empirical formulas for product ions

were generated using Mass Hunter Workstation Software Qualitative Analysis.

2.4. RESULTS
In order to understand the mechanism of PFAM CID a select group containing
lauramide (C12:0), myristamide (C14:0), palmitamide (C16:0), oleamide (C18:1 9),
elaidamide (C18:19t), petroselaidamide (C18:16t), stearamide (C18:0), arachidamide
(C20:0), erucamide (C22:113), and behenamide (C22:0) were directly infused into an
electrospray ionization source coupled to a QToF. N-acyl glycine (NAG) fragmentation
patterns were obtained via direct infusion into an electrospray ionization source, operated
in negative mode, coupled to a triple quadrupole mass spectrometer. All PFAM parent
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ions were observed as the [M + H]+ ion and NAGs as the [M - H]-. Fragmentation
patterns for both classes of fatty acyls were obtained at collision energies from 20 -100 V
(Figure 2-1). As the collision energy increased the patterns were dominated by the
occurrence of smaller product ions. Empirical formula generation suggested that the
fragmentation pathways for all saturated PFAMs were similar regardless of the acyl chain
length. All MS/MS spectra contained an acyl chain fragment observed at 57 m/z (Figure
2-2). Additionally, several fragment ions were identified by isotope ratio analysis to
contain both nitrogen and oxygen. This is observable in both the parent ion mass and
isotope distribution. The parent ion mass is an odd number value (if the additional proton
charge is removed) which is attributed to the single nitrogen atom present in the structure.
The major parent ion peak is comprised of the most stable atomic isotopes. Peaks of
greater mass in the ion cluster are compounds containing the lesser abundant isotopes. In
these examples a peak at 2 m/z greater than the parent ion is due to the 0.204%
probability of the compound containing 18O. In this way isotope ratio analysis was used
to determine the empirical formulas for each major product ion. The product ions were
interpreted to be fragments which contain the head group carboxamide but differ by the
acyl chain fragmentation point. As the acyl tail length was increased, the occurrence of
higher mass product ions increased, and differed by 14 m/z.

This supported the

hypothesis that the acyl chain fragmentation point was variable. An isotopically labeled
palmitamide (13C-1-hexadecanoamide) was used to confirm the identity of the proposed
head group fragments. In this case the product ions containing the head group carbon
would be mass shifted by 1 amu (Figure 2-3A), while the acyl chain fragment at 57 m/z
would remain unchanged.

These suspected product ion assignments were used to
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propose a fragmentation mechanism for the saturated PFAMs. The head group fragments
form by β-hydrogen rearrangement causing the product ion to terminate with a methyl,
while the remainder of the acyl tail was lost as a neutral fragment (Figure 2-3B). An
alternate fragmentation mechanism to that proposed is homolytic cleavage of the carboncarbon bond with radical hydrogen transfer, as described by Wysocki and Ross.103 This
type of fragmentation was most common at carbons 3-6 from the carboxamide moiety
(for collision energies of 20-35 V), producing the largest observed alkyl loss. The acyl
chain fragment was proposed to form through bond rearrangement to produce a singly
charged acyl fragment. The secondary product then undergoes a hydrogen rearrangement
from the carboxamide ion to the alkene tail resulting in a neutral loss (Figure 2-3C). This
was supported by product ion peaks, as no doubly charged head group fragment was
observed. An alternative fragmentation mechanism for acyl tail formation could involve
β-hydrogen rearrangement within the acyl tail, and a bond rearrangement at a position of
4 or less carbons away. This type of fragmentation would produce a neutral loss of an
alkene chain, an acyl chain fragment of 57 m/z or less, and a doubly charged
carboxamide fragment that would undergo hydrogen rearrangement previously described,
to result in another neutral loss. Both acyl chain fragmentation pathways are probable, as
product ions of 43 and 29 m/z can be observed on MS with mass scanning capabilities
below 50 m/z (data not shown).
Monounsaturated PFAMs had a distinct fragmentation pattern when compared
with saturated PFAMs (Figure 2-4). The major difference was the loss of 17 and 35 m/z
indicating the loss ammonia, and both ammonia and water from the carboxamide. These
losses were verified by empirical formula analysis, and have been previously reported. 15
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The remaining product ions were identified as alkyl chains of varying length, as well as
the acyl fragment of 57 m/z that was observed in the saturated PFAM fragmentation
patterns. Because all the product ions were identified as alkyl chains, it was postulated
that the loss of water and ammonia was a fast process resulting in a positively charged
alkyl fragment of m/z 247 (Figure 2-5A). The loss of ammonia and water gave rise to
product ions 265 and 247 m/z.

These ions have been observed in similar CID

experiments conducted on phosphotidylcholines.104 This 247 m/z alkyl carbocation would
then fragment and give rise to the remaining product ions observed. Changing the length
of the acyl chain or the position/stereochemistry of the double bond did not alter the
observed product ion masses.

This could be explained by hydrogen rearrangement

causing double bond labiality, as depicted in Figure 4B. The product ions observed at 83
and 69 m/z arise from charge directed fragmentation of the 247 m/z alkyl carbocation, as
depicted in Figure 4C. An isotopically labeled oleamide ( 13C2-9, 10-octadecanoamide)
fragmentation pattern was examined to determine bond cleavage points (Figure 2-5). 135
m/z product ion was calculated to have an empirical formula of C 10H15 and to contain
both isotope labels. This suggests that the fragmentation point was just to the left of the
double bond position. Likewise, 121 m/z empirical formula was C 9H13 and contained just
one

13

C label, indicating a cleavage at the double bond position. This result confirmed

the proposed mechanism shown in Figure 2-4B. The product ions observed at 83 and 69
m/z were not mass shifted due to

13

C labeling, confirming the proposed charge directed

fragmentation mechanism (Figure 2-4C).
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Figure 2-1. CID of 10 µM standards of A: stearamide, B:
oleamide, and C: oleoylglycine directly infused at 0.50
mL/minute using a Harvard A11 syringe pump into a
Agilent 6460 triple quadrupole. The collision energy was
varied and is depicted in the legend of each figure.
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Figure 2-2. Product ion scans of saturated PFAMs from CID-MS. A: Lauramide (C12:0),
B: myristamide (C14:0), C: palmitamide (C16:0), D: stearamide (C18:0), E: arachidamide
(C20:0), and F: behenamide (C22:0). All samples were approximately 10 µM and were
directly infused into an ESI-QToF at a rate of 500 µL/min. Collision energy was set to 20
V for each sample except behenamide (C22:0) which was collected at 35 V.
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Figure 2-3. A: Product ion scans of palmitamide (black) and 13C-1-palmitamide (red).
All samples were approximately 10 µM and were directly infused into an ESI-QToF at
a rate of 500 µL/min with a collision energy of 20 V. The top trace is offset on the yaxis by 100 units. B: Proposed β-hydrogen rearrangement resulting in the head group
containing fragments. The * denotes the position of 13C in case of isotopically labeled
analyte. C: Proposed bond fragmentation to yield a 57 m/z product ion.
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Figure 2-4. Product ion scans of monounsaturated PFAMs from collision induced
dissociation MS at a CE of 20 V. A: oleamide (C18:19), B: elaidamide (C18:19t), C:
petroselaidamide (C18:16t), and D: erucamide (C22:113). All samples were approximately
10 µM and were directly infused into an ESI-QToF at a rate of 500 µL/min.
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Figure 2-5. A: Proposed mechanism for the loss of ammonia and water from
PFAMs. B: Hydrogen rearrangement resulting in double bond movement and
fragmentation to yield the observed alkyl product ions. C: Charge directed
fragmentation resulting in product ion 69 m/z and a neutral loss.

Figure 2-6. Product ion scans of oleamide (bottom trace) and 13C2-9, 10-oleamide (top
trace). All samples were approximately 10 µM and were directly infused into an ESIQToF at a rate of 500 µL/min. Both spectra were collected at 20 V collision energy.
The top trace is offset on the y-axis by 100 units. The most abundant peak in the ion
cluster was mass labeled.
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Figure 2-7. CID pattern of 10 µM oleoylglycine standard directly infused at 0.50
mL/minute using a Harvard A11 syringe pump into a Agilent 6460 triple quadrupole
equipped with an ESI source operated in negative mode. The parent ion was observed as
the [M – H]-. The most abundant peak in the ion cluster was mass labeled. The molecular
structure shows the proposed bond fragmentation site.

The group of product ions between 105 and 118 m/z was scrutinized because of the
differences in relative intensity between isobars. In a double blind test the change in
relative intensity between the product ions in the group, though not significant, was
enough to obscure accurate identification (data not shown).
Oleoylglycine fragmentation pattern (Figure 2-7) has an [M – H]- parent ion and
displayed major product ions of 294 and 74 m/z. Upon inspection of the molecular
structure the product ion 74 m/z was proposed as the deprotoned form of the glycine head
group. The remaining product ion revealed a similar fragment loss of 57 m/z that was
observed in the saturated PFAM CID (Figure 2-2). This ion was not observed in the
oleoylglycine spectra as the 57 m/z occurs as the positive ion.

2.5. DISCUSSION AND CONCLUSION
CID patterns of saturated and monounsaturated PFAMs, ranging in acyl chain
length from 12 to 22, were collected and analyzed to determine the empirical formulas of
the product ions. The saturated PFAMs were found to contain similar product ion peaks
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containing carbon, oxygen, hydrogen, and nitrogen except for the product ion 57 m/z,
which contain carbon and hydrogen. Product ion peaks containing nitrogen and oxygen
were proposed to be fragments including the carboxamide head group and differing in the
acyl fragmentation site. The 57 m/z product ion, present in both the saturated and
monounsaturated PFAMs, was identified as an acyl chain fragment. The fragmentation
patterns observed for saturated PFAMs are similar to patterns observed for fatty acids
analyzed in positive mode as lithium adduct ions. 103,105

Both display product ions

separated by 14 m/z units which is characteristic of acyl chain lipids. Additionally, bond
fragmentation within the acyl chain occurs by similar charge remote fragmentation
mechanisms.103,106,107

One distinct difference between fatty acid and PFAM

fragmentation is the charged fragment does not terminate in an alkene in the latter case.
This change can either occur directly by β-hydrogen rearrangement before alkane bond
cleavage or by radical hydrogen attachment after a homolytic bond fragmentation (Figure
2-2B). The product ions observed do not support the typical pericyclic 1,4 hydrogen
elimination mechanism reported for fatty acid CID. Additionally, at the collision energy
tested, no loss of water or ammonium was observed from the carboxamide of saturated
PFAMs, as is sometimes seen in fatty acid or fatty amide CID. 103,108,109
The defining characteristic of the monounsaturated PFAM fragmentation patterns
was the [M + H -17] and the [M + H – 35] product ion peaks, indicating the loss of
ammonia and water from the carboxamide head group. These two product ion peaks, as
well as the acyl tail signature, can be diagnostic of PFAMs when observed in typical
biological systems. The remaining fragments were identified as alkyl chain fragments.
Increasing chain length increased the appearance of higher mass product ions when
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exposed to constant collision energy. The product ions are expected to be terminal
alkenes, however observed masses do not support a pericyclic fragmentation mechanism.
A change in the position or stereochemistry of the double bond did not change the
product ions observed, consistent with previously reports of unsaturated fatty acids. 110
For this reason, the identity of isobaric compounds could not be differentiated.
Therefore, if isomer identification by MS alone is necessary, the double bond should first
be derivatized to prevent labiality110 or a front end LC method capable of separating
isobars must be developed.
In contrast to the PFAMs, NAGs occur as [M – H]- parent ions. The major ions
observed in the oleoylglycine fragmentation pattern 294 and 74 m/z. These ions were
proposed to be the deprotonated form of glycine at 74 m/z. Product ion 294 m/z exhibited
a loss of 57 m/z and was proposed to lose this fragment via hydrogen rearrangement
similar to the mechanism proposed for saturated PFAMs. No charge rearrangement
occurs in this case and the positive 57 m/z ion is not observed in negative ion mode.
The important role of lipids in biology and health, as well as the emergence of
sensitive detection platforms utilizing mass spectrometry, have driven the field of
lipidomics (recently reviewed in a special Chemical Review issue on “Lipid
Biochemistry, Metabolism, and Signaling”). 111 Despite the physiological significance of
PFAMs2-18 (see Chapter 1: Metabolism, Physiology, and Analyses of Primary Fatty
Acid Amides) , this class of lipids have not been extensively characterized and is not
well represented in the LIPID Metabolites and Pathways Strategy (LIPID MAPS)
consortium site (www.lipidmap.org). 112 In this work we have reported CID patterns for
various saturated and monounsaturated PFAMs and successfully employed isotope
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labeled compounds to elucidate fragmentation mechanisms, providing essential
information necessary for further analytical studies on this class of lipids.
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Chapter 3

Chromatographic Separation Methods for Fatty Acyls
3.1. ABSTRACT
The view of lipids in biochemistry is expanding as numerous fatty acyls are
discovered to possess signaling properties. These signaling lipids are often found in
quantities of pmol/g of tissue and are co-extracted with numerous lipophilic molecules,
making their detection and identification challenging. Common analytical means involve
chromatographic separation and MS techniques; however, a single step is typically
inefficient due to the complexity of the sample. It is, therefore, essential to develop
approaches that incorporate multiple dimensions of separation. Described in this chapter
are normal phase, reversed phase, and silver ion separation strategies for fatty acyls that
included tandem MS as a detection method and additional means of separation and
identification. These approaches are intended to be used in concert to accommodate
quantitation of highly complex samples.

3.2. INTRODUCTION
Lipids are typically viewed in terms of constituents of cellular membranes and
modes of energy storage; however, many lipids exert bioactive properties through cellular
signaling means. NAEs have a long history of physiological and G-protien receptor
mediated effects that are directly related to, or reminiscent of, cannabinoid activation 113116

.

PFAMs and NAGs, however, are just beginning to be recognized as bioactive

signaling lipids that have demonstrated interactions with serotonin receptors4-7, gap
junction proteins and calcium signaling57,67,70-72, and a myriad of physiological
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effects11,15,17,19,52-54,56,117-119 (see Chapter 1: Metabolism, Physiology, and Analyses of
Primary Fatty Acid Amides) . Of these documented effects, the most potent bioactive
lipids consist of 16-22 chain length acyl tails and can be saturated or unsaturated species.
In addition, it is hypothesized that aberrant endogenous levels of these species, either by
down-stream modulation or alteration of their metabolic enzymes, could contribute to
disease states. This is an intriguing consideration as PFAMs are known to have high
affinity for serotonin receptors, though no reports exist for PFAM levels in this disease
phenotype. Evidence for up-regulation of NAEs exists in studies of chronic pain120,
schizophrenia121, depression and anxiety122, yet the physiological relevance of these
observations is still unclear. In light of this, it is of substantial importance to develop
analysis strategies for bioactive fatty acyls.

These methods, in combination with

phenotype studies, will aid in the elucidation of the role of signaling lipids and disease
states. The generated methodologies may provide additional tools for diagnosis and
development of treatment strategies.
Lipid milieus of biological samples are often very complex mixtures. Even the
most common lipid extraction methods, such as Folch-Pi86, remove a mélange of several
different lipid classes.

Identification of isomers and isobars by standard separation

methods, such as normal phase and reversed phase chromatography, is often insufficient
for complete identification of all constituents. Silver ion chromatography has been used
extensively for separation of lipid samples with a high variation of unsaturation numbers
of geometrical configuration123-134. However, silver ion separations cannot differentiate
between trans-unsaturated and saturated analytes.
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Multidimensional liquid chromatography (MDLC) analysis is the process of
injecting samples onto a liquid chromatography system where two different separation
schemes (columns or dimensions) are used135-139. The main advantage of MDLC is the
dramatic increase in peak capacity known as the “product rule”; where the maximum
peak capacity becomes the product of the two individual chromatographic peak
capacities.

These different separation schemes must be orthogonal, or operate by

different separation mechanisms, in order to achieve maximum capacity. Analysis by
two different chromatographic dimensions allows for the separation of difficult to resolve
components or samples with a high number of constituents.
There are several terms for describing multidimensional systems. The first is a
distinction between online and off-line systems. An on-line system uses a switching valve
to divert fractions of the 1 st dimension flow directly to the 2nd dimension. Off-line
systems use two different chromatography steps where the sample is collected from the
first dimension, dried down and reconstituted for injection into a second system.
For online MDLC the 2 nd dimension separation must be very fast so that extreme
band broadening due to longitudinal diffusion is minimal in the 1 st dimension. One option
for shorter analysis times is the use of columns with particle sizes smaller than 3 μm. The
reduction in particle sizes results in a decrease in the resistance to mass transfer between
the two phases. This allows the analysis to be run at an increased linear velocity, thereby,
reducing the analysis time. Additionally, the plate height is decreased as the square of the
particle size according to the van Deemter relationship 140-142. Since plate height is
inversely related to peak resolution, this produces a more efficient separation between
analytes.
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Additionally, the switching valve timing, the amount of time between loop
switching (process that diverts small eluent fractions from the 1 st dimension to the 2nd
dimension for analysis), and loop size must be determined after successful method
development of both dimensions. Both methods have the advantage that if separation
mechanisms between dimensions are orthogonal then maximum peak capacity is
achieved. Off-line systems are advantageous because there is no concern of sample
solvent miscibility between separation dimensions. However, the analysis time is
generally longer because samples have to be processed between separations.
Silver ion chromatography is a method for separating molecules with different
degrees of unsaturation. The general mechanism of action in this separation scheme is
unclear, though, Christie and co-workers propose a theory of silver ions forming weak,
reversible charge transfer complexes with the analytes128,143-145. Another possibility is an
intermolecular ion-dipole interaction between the loaded silver ions on the
chromatographic bed and the π bonds of the analyte. In general, elution order of analytes
by this technique is saturated, trans-unsaturated, mono-unsaturated, and so on. A number
of experimental parameters and analyte variables have been explored in relation to
retention factor allowing implementation of this methodology in a predictable
manner127,146,147. One exception to typical chromatographic separations is that retention
of analytes in silver ion chromatography is reduced at lower temperature 148.
Both online and offline MDLC separations have been demonstrated for TAGs in
plant and animal samples131-134. Each approach utilized a reversed phase separation with
an isopropanol/acetonitrile gradient and an isocratic silver ion separation with 0.5-0.7%
acetonitrile in hexane. Samples that were separated with an online MDLC approach
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always had a reversed phase 2nd dimension separation with a total analysis time of less
than 2 minutes131,133. MDLC has not yet been demonstrated with PFAMs and NAGs,
although or laboratory has utilized an SPE method prior to GC-MS analysis149. The
following sections demonstrate various separation methods for PFAMs, NAGs, and fatty
acid phenacyl esters. We additionally propose an offline separation method for future
utilization.

3.3. MATERIALS AND METHODS
3.3.1 Chemicals
Methanol optima grade, formic acid optima grade, ammonium acetate, silver
nitrate, hexane, dichloromethane, acetonitrile, and ammonium hydroxide were purchased
from Fisher Scientific (Fair Lawn, NJ, USA). Oxalyl chloride, oleic acid, erucic acid,
petroselaidic acid, heptane HPLC grade, methyl-tert-butyl-ether HPLC grade,
isopropanol HPLC grade, acetic acid, and anhydrous dichloromethane were from Sigma
Aldrich (St Louis, MO, USA).

N, N-dimethylformamide, heptadecanoic acid, and

eicosanoic acid were purchased from Aldrich Chemical Company (Milwaukee, WI,
USA). Lauric acid, myristic acid, palmitic acid, stearic acid, and docosanoic acid were
purchased from Acros Organics (New Jersey, USA).

Elaidic acid was from MP

Biomedical Inc. (Solon, OH, USA) and linoleamide was purchased from Enzo Life
Sciences (Ann Arbor, MI, USA). Oleoylglycine, Linoleoylglycine, palmitoylglycine,
arachidonoylglycine, and arachidoylglycine were purchased from Cayman Chemicals
(Ann Arbor, MI, USA).
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3.3.2 Normal Phase Separation
PFAM and NAG standards were prepared in a mixture at 1 mM concentration of
each standard. The mixture was separated via normal phase chromatography utilizing a
YMC PVA-Sil column (4.6 × 250 mm, 5 µm particle size). Gradient elution is carried
out starting at 95 % mobile phase A (heptane with 0.5% v/v methyl-tert-butyl-ether) and
increasing linearly to 50% mobile phase B (methyl-tert-butyl-ether with 10% v/v 2propanol and 0.2% v/v acetic acid) over 40 minutes with a flow rate of 1 mL/minute
(gradient developed by Kroniser and Johnson, unpublished). Fractions were collected at
one minute intervals and the times corresponding to NAG and PFAM elution are
determined by reversed phase chromatography and MS/MS detection.

3.3.3 Silver Ion Chromatography
Select saturated, monounsaturated, and di-unsaturated fatty acids were derivatized
to fatty acid phenacyl esters (FAPEs) by reaction of excess 2-bromoacetophenone and a
triethylamine catalyst in an acetone solvent carried out in sealed culture tubes that were
placed in a boiling water bath for approximately 45 minutes150. After 45 minutes the
reaction was cooled to room temperature and then an acetic acid solution was used to
convert any unused 2-bromoacetophenone reagent to phenacyl acetate.

Prior to

separation the reaction solution was dried under nitrogen and reconstituted in hexane.
The silver ion column was prepared from a Waters Spherisorb SCX column (4.6
× 150 mm, 5 µm particle size) by injection of 20 µL aliquots of 10% aqueous silver
nitrate solution to a total volume of 1 mL. After the silver ions were loaded onto the
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cation exchange column, the system was flushed for one hour, and then stored in a
hexane solvent.
10 μM FAPE samples were analyzed on the prepared silver-ion column connected
to a Waters 600 HPLC system equipped with a Waters 2487 Dual λ Absorbance Detector
operated at a wavelength of 250 nm. A 20 μL loop was used for sample loading and
elution

was

achieved

using

a

solution

of

59.7/39.8/0.5

hexane/dichloromethane/acetonitrile in isocratic mode with a flow rate of 1 mL/minute.

3.3.4 Reversed Phase Separation of N-acyl Glycines
Palmitoylglycine,

linoleoylglycine,

oleoylglycine,

stearidonoylglycine,

arachidonoylglycine, and arachidoylglycine were analyzed on an Agilent Technologies
1200 Liquid Chromatography system with a 6460 Triple Quadrupole Mass Spectrometry
Detector.

Mobile phase A was methanol and mobile phase B water both contained 10

mM ammonium acetate. Separations were carried out on a YMC Cartenoid column (4.6
× 150 mm, 5 µm particle size) with a linear gradient of 90% to 100% mobile phase A
over 15 minutes with a 15 minute hold time. An additional separation method was
developed on a Phenomenex C18 column (4.6 × 100 mm, 2.6 µm particle size) with a
linear gradient of 80% to 100% mobile phase A over 5 minutes and a 2 minute hold time.
A second gradient method was used and consisted of 70% mobile phase A hold for 7
minutes, a linear gradient increase to 80% for 7 minutes, a 1 minute hold at 80% before
increasing to 100% mobile phase A over 5 minutes, and a final 5 minute hold for a total
analysis time of 25 minutes.

55

Ionization was achieved with an ESI source operated in negative mode with
optimized parameters: fragmentor voltage 135 V, sheath gas flow 11 L/minute, nebulizer
pressure 55 psi, nozzle voltage 500 V, capillary voltage 3500 V, drying gas flow 9
L/minute, drying gas temperature 275oC, and dwell time of 500 ms. Multiple reaction
monitoring parameters were set-up to analyze the [M – H]- parent ions and 74 m/z
product ion.
3.3.5 Reversed Phase Separation of Primary Fatty Acid Amides
All primary fatty acid amide standards were synthesized in house at greater than
98% purity (Chapter 2 Section 3.2 PFAM synthesis). Lauramide (C12:0), myristamide
(C14:0), linoleamide (C18:29,

12

), palmitamide (C16:0), oleamide (C18:19), elaidamide

(C18:19trans), petroselaidamide (C18:16trans), heptadecanoamide (C17:0), stearamide
(C18:0), arachidamide (C20:0), erucamide (C22:113), and behenamide (C22:0) were
separated on a Agilent RP C18 column (2.0 × 50 mm, 1.8 µm particle size) with a
gradient elution of methanol, optima grade and water both containing 0.3% formic acid.
PFAMs were detected using an Agilent 6460 Triple Quadrupole Mass
Spectrometer equipped with an atmospheric pressure chemical ionization (APCI) source.
Optimized detection parameters are as follows: gas temperature 325oC, vaporization
temperature 325oC, gas flow 4 L/minute, nebulizer pressure 22 psi, capillary voltage
3500 V, corona 4 µA, and fragmentor 125 V. Multiple reaction monitoring was used to
detected the [M + H]+ parent ions and product ions of 55 and 43 m/z for the
monounsaturated and saturated compounds respectively.

56

3.4. RESULTS
3.4.1 Normal Phase Separation
A 975 nmol lipid mixture of fatty acids (FA), triacylglycerols (TAG),
diacylglycerols (DAG), monoacylglycerols (MAG), NAGs, PFAMs, and NAEs standards
were separated by normal phase chromatography (Figure 3-1. Kroniser and Johnson,
unpublished).
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Figure 3-1. Chromatogram of seven fatty acyl subclasses separated by normal phase
chromatography using a YMC PVA-Sil (4.6 × 250 mm, 5 µm particle size) on a Waters ZMD MS
with an ESI probe with polarity switching. Separation was achieved with mobile phase A (heptane
with 0.5 % methyl-tert-butyl ether) and mobile phase B (10% 2-propanol, 0.2% acetic acid in
methyl-tert-butyl ether) run in gradient mode from 95% to 50% A over 40 minutes. The
monoacylglycerol (MAG) were monitored as the [M+Na]+ peak, PFAM as the [M+H]+ peak, DAG
as [M+Na]+ peak, NAE as [M+Na]+ peak, FA as [M-H]- peak, NAG as [M-H]- peak, and TAG
[M+Na]+ peak. Each class was monitored on a different channel on the MS.

Sample injection volume was increased from 20 µL to 200 µL to accommodate larger
scale sample purification needs. The effect of the increased injection volume on elution
was tested by collecting one fraction per minute over the total analysis time. These
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fractions were dried down, reconstituted in methanol, and analyzed by reversed phase
methods (Figure 3-2). The NAGs and PFAMs were found to co-elute from 31 to 38
minutes (Figure 3-2B, C). Co-elution was determined not to be problematic because
these species ionize in different modes for reversed phase MRM analysis (see 3.4
Reversed Phase Separation of N-acyl Glycines and 3.5 Reversed Phase Separation of
Primary Fatty Acid Amides).

Figure 3-2. (A)Representative chromatogram of fractional PFAM elution from normal
phase chromatography collected from 34-35 minutes. Fraction was dried down,
reconstituted in methanol and analyzed on an Agilent RP C18 (2.0 × 50 mm, 1.8 µm
particle size) with methanol/water gradient elution. 0.3% formic acid was added as an
ionization aid and multiple reaction monitoring was used. (B) PFAM and (C) NAG
standards eluted from the normal phase chromatography separation on a YMC PVA-Sil
column (4.6 × 250 mm, 5µm particle size) with gradient elution (see 3.2 Normal Phase
Separation for gradient information). Fractions were collected each minute, dried and
reconstituted in methanol. Fractions were analyzed by reversed phase chromatography.
All peaks observed in each fraction were summated and represented as the peak area per
fraction.
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3.4.2 Silver Ion Chromatography
FAPEs were prepared from select fatty acids ranging in carbon chain length from
12 to 22 and 0 to 2 degrees of unsaturation. Successful derivatization was confirmed by
UV-visible and FT-IR spectroscopy (data not shown). Thin layer chromatography also
confirmed synthesis of the FAPE from oleic acid by an R f value of 0.406 which was in
good agreement with literature reports129. Addition of acetic acid to the FAPE reaction
mixture after heating was necessary to prevent excess 2-bromoacetophenone from
degrading the FAPE products. A mixture of stearic, oleic, and linoleic acid phenacyl
esters were prepared and separated on a strong cation exchange column loaded with
silver ions (Figure 3-3A). Elution order was determined by individual injection of each
of the FAPEs. An additional peak was present in each of the chromatograms that was
due to excess phenacyl bromide reagent, therefore, the individual products and mixture
was spiked with phenacyl bromide to confirm elution time. Stearic acid phenacyl ester
was found to elute first followed by excess phenacyl bromide, oleic acid phenacyl ester,
and linoleic phenacyl ester.
The effect of chain length on separation was determined by injection of saturated
FAPEs from 14 to 20 carbons as both individual FAPEs and as a mixture (Figure 3-3B).
It was found that the saturated FAPEs co-eluted as one peak with the longer chain FAPEs
eluting near the beginning of the mixture. This co-elution trend did not continue with
increasing degrees of unsaturation as distinct peaks were observed for oleic acid phenacyl
ester and erucic acid phenacyl ester (Figure 3-4).
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Figure 3-3. (A) FAPE elution by silver ion chromatography with an isocratic mobile phase of
59.7/39.8/0.5 hexane/dichloromethane/acetonitrile at a flow rate of 1 mL/minute and UV
monitoring at 250 nm. (1) Stearic acid phenacyl ester, (2) phenacyl bromide, (3) oleic acid
phenacyl ester, (4) linoleic acid phenacyl ester. The red trace is elution of the mixture of FAPEs
and the black trace shows the mixture that was spiked with phenacyl bromide reagent. Both
traces were normalized to the intensity of (4) to account for absorbtion variability between runs.
(B) Saturated FAPEs elution by silver ion chromatography with an isocratic mobile phase of
59.7/39.8/0.5 hexane/dichloromethane/acetonitrile at a flow rate of 1 mL/minute and UV
monitoring at 250 nm. Elution order is as follows: behenic acid phenacyl ester (C22:0, red),
arachidic acid phenacyl ester (C20:0, orange), stearic acid phenacyl ester (C18:0, yellow),
palmitic acid phenacyl ester (C16:0, green), myristic acid phenacyl ester (C14:0, blue). The
mixture of C14:0 to C22:0 is shown in black.
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Figure 3-4. Elution of FAPEs by silver ion chromatography with an isocratic mobile
phase of 59.7/39.8/0.5
hexane/dichloromethane/acetonitrile at a flow rate of 1
mL/minute and UV monitoring at 250 nm. (1) saturated FAPEs C14:0 to C22:0, (2)
excess phenacyl bromide, (3) erucic acid phenacyl ester, (4) oleic acid phenacyl ester,
(5) eicosadienoic acid phenacyl ester, (6) linoleic acid phenacyl ester.

3.4.3 Reversed Phase Separation of N-acyl Glycines
Palmitoylglycine (C16:0), oleoylglycine (C18:19 ), linoleoylglycine (C18:29,12),
stearidonoyolglyicne

(C18:46,9,12,15),

arachidonoylglycine

(C20:45,8,11,14),

and

arachidoylglycine (C20:0) were separated utilizing a C30 YMC carotenoid column and a
fused-core Phenomenex C18 column.
Separation of palmitoylglycine (C16:0), oleoylglycine (C18:1 9), linoleoylglycine
(C18:29,12), and arachidoylglycine (C20:0) was achieved on a C30 YMC carotenoid
column (4.6 × 150 mm, 5 µm particles size) with gradient elution of methanol and water.
Both mobile phases were modified with 10 mM ammonium acetate to aid in ionization.
Elution was achieved by linear increase in methanol from 90-100% over 15 minutes,
followed by a 15 minute hold. Elution of each component was determined by the parent
mass (Figure 3-5A).
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Figure 3-5. Separation of NAGs on (A) a C30 YMC carotenoid column (4.6 × 150 mm, 5 um
particles size) and (B, C) Phenomenex C18 column (4.6 × 100 mm, 2.6 µm particles size) using two
different gradient separations. Ionized by ESI and detected in MRM mode as the [M-H]- parent and
74 m/z product at collision energy of 20 V. Flow rate was 1 mL/min. The right axis shows the
gradient elution profile for % methanol. Peak identities in (A, B) are (1) linoleoylglycine C18:2, (2)
palmitoylglycine C16:0, (3) oleoylglycine C18:1 , (4) arichidoylglycine C20:0 and (C) are 1)
stearidonoylglycine C18:4, (2) linoleoylglycine C18:2, (3) arachidonoylglycine C20:4, (4)
palmitoylglycine C16:0, (5) oleoylglycine C18:1, (6) arachidoylglycine C20:0.

In an effort to reduce the analysis time, a fused-core Phenomenex C18 column (4.6 × 100
mm, 2.6 µm particles size) was employed using methanol/water gradient elution (Figure
3-5B). The use of a fused-core particle C18 column reduced the experimental time by 6
fold compared to the C30 column separation while simultaneously increasing resolution.
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A second elution method was developed (Figure 3-5C) using the fused-core C18
column to determine elution of two additional analytes, arachidonoylglycine
(C20:45,8,11,14) and stearidonoylglycine (C18: 46,9,12,15). Although the total analysis time
was increased 4 fold compared with the previous gradient method (Figure 3-5B); coelution between linoleoylglycine (C18:2) and arachidonoylglycine (C20:4) was avoided.
Utilizing the method developed in Figure 3-5 the ionization parameters were
optimized to yield the lowest detection limit possible (see 3.4 Reversed Phase
Separation of N-acyl Glycines for final parameters). The limit of detection for each
analyte was determined by 5 µL injection of standards between 100 nM and 10 µM. The
results for limit of detection (LOD = signal to noise ratio, S/N, 3) and limit of
quantitation (LOQ = S/N 5) are shown in Table 3-1. The calibration curves were linear
(see Table 3-1 R2 value) between 1 – 10 µM.
N-acyl glycine
Stearidonoylglycine
Linoleoylglycine
Arachidonoylglycine
Palmitoylglycine
Oleoylglycine
arachidoylglycine

Abbreviation
C18:46, 9, 12, 15
C18:29, 12
C20:45, 8, 11, 14
C16:0
C18:29
C20:0

LOD (µM)
0.475
0.499
0.484
1.00
1.00
1.00

LOQ (µM)
1.00
1.00
1.00
1.00
1.00
1.00

R2
0.999
0.999
0.999
0.994
0.999
0.999

Table 3-1. LOD and LOQ for several commercially available NAGs determined by injection of 5
µL standard solutions from 100 nM to 10 µM. Calibration curves were linear between 1 - 10 µM.
The LOD and LOQ were determined by a S/N of 5 and 10, respectively.
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3.4.4 Reversed Phase Separation of Primary Fatty Acid Amides
Very long chain PFAMs (C12 to C22) were separated via reversed phase
chromatography employing a sub 2 µm particle size column (Agilent RP C18 2.1 × 50
mm, 1.8 µm particle size). The shortest separation achieved was a 4 minute total analysis
time (Figure 3-6).

Figure 3-6. Separation of very long chain PFAMs with Agilent RP C18 column (2.1 × 50
mm, 1.8 µm particle size) using 4 different gradient separations. Peak identities for (A-C)
are (1) lauramide, (2) myrstamide, (3) palmitamide, (4) oleamide, (5) elaidamide, (6)
petroselaidamide, (7) heptadecanoamide, (8) stearamide, (9) erucamide, (10) arachidamide,
(11) behenamide. Peak identities for (D) are (1) lauramide, (2) myrstamide, (3) linoleamide,
(4) palmitamide, (5) oleamide, (6) elaidamide, (7) petroselaidamide, (8) stearamide, (9)
erucamide, (10) arachidamide, (11) behenamide. The right axis depicts the gradient elution
in % methanol.

Due to the co-elution of oleamide, elaidamide, petroselaidamide, and
heptadecanoamide additional gradients were developed (Figure 3-6A-D) in an effort to
eliminate co-elution while maintaining the shortest analysis time possible.
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A longer gradient elution was established (Figure 3-6C), with a longer initial hold
and slower ramp in percent methanol, to determine if petroselaidamide and
heptadecanoamide could be resolved.

The 20 minute gradient was insufficient to

separate the two components; additionally, further increasing the hold, ramp time, or
temperature simply increased peak broadening with no increase in resolution (data not
shown). Heptadecanoamide was monitored with a separate method in future experiments
due to the co-elution with petroselaidamide.

A final gradient (Figure 3-6D) was

constructed in an effort to maintain the resolution of oleamide, elaidamide, and
petroselaidamide as well as reduce the analysis time. The final analysis time was reduced
by approximately 2 fold and this gradient method was used in all future experiments for
detecting PFAMs.
Utilizing the separation method developed in Figure 3-6D the optimized
ionization parameters for greatest detection sensitivity were determined (see 3.5
Reversed Phase Separation of Primary Fatty Acid Amides for final parameters). The
limit of detection for each analyte was determined by 2 µL injection of standards between
500 pM and 10 µM. The results for limit of detection (LOD = signal to noise ratio, S/N,
3) and limit of quantitation (LOQ = S/N 5) are shown in Table 3-2. The calibration
curves were linear (see Table 3-2 R2 value) between 0.500 – 10 µM on average. In cases
where the LOD and LOQ were equal the signal was lost below the LOD, however, at this
concentration the S/N was above 5.
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PFAM
Lauramide
Myristamide
Linoleamide
Palmitamide
Oleamide
Elaidamide
Petroselaidamide
Stearamide
Erucamide
Arachidamide
behenamide

Abbreviation
C12:0
C14:0
C18:29, 12
C16:0
C18:19
C18:19trans
C18:16trans
C18:0
C22:113
C20:0
C22:0

LOD (nM)
50
50
10
20
400
40
40
50
50
10
20

LOQ (nM)
100
50
50
50
400
400
400
50
100
50
20

R2
0.999
0.999
0.999
0.999
0.999
0.998
0.999
0.997
0.998
0.999
0.999

Table 3-2. LOD and LOQ for select PFAMs determined by injection of 2 µL standard
solutions from 500 pM to 10 µM. Calibration curves were linear between 0.500 - 10 µM.
The LOD and LOQ were determined by a S/N of 5 and 10, respectively.

3.5. DISCUSSION AND CONCLUSION
This chapter describes various strategies for efficient separation and detection of
saturated and unsaturated fatty acyls. Different subclasses of lipids were resolved with a
normal phase separation scheme utilizing a heptane and methyl-tert-butyl ether
substituted mobile phase with gradient elution. The addition of isopropanol to the mobile
phase was necessary to increase the solubility of these lipids, reducing the carry over
between injections. Nonetheless, it was still essential to occasionally wash the column
with polar solvents, especially if large injection volumes (> 100 µL) are used frequently.
The fatty acyl subclasses separated via the normal phase method are those commonly
extracted with Folch-Pi from biological samples.

This method is comparable to

previously reported SPE methods149 and although it has an increased total analysis time
the separation is automated and highly reproducible. The eluent can be monitored by MS
if a post-column feed is used or collected directly for further separation or analysis. It
was found that, with a 200 µL injection volume, the PFAMs and NAGs would co-elute as
one peak between 31 and 38 minutes. This, however, was not problematic as further
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analysis conducted with MS/MS found that NAGs ionized in the negative mode while
PFAMs were observed in positive mode.
Silver ion chromatographic separation of analytes with various degrees of
unsaturation was employed to determine its viability as a technique in multidimensional
chromatography of fatty acyls. Argenation chromatography by TLC and GC were first
described in the 1960’s151,152. Later versions involving HPLC were reproduced in our
laboratory. In our hands it was observed that the saturated and trans-unsaturated fatty
acid phenacyl bromides co-eluted as one peak.

Subsequently, mono-unsaturated

components eluted, followed by di-unsaturated, and so on.

Unlike the saturated

components, secondary separation occurred where all components with the same degrees
of unsaturation did not co-elute. This was attributed to the column having “uncapped”
silinol groups causing a secondary normal phase separation. This separation scheme was
found to suffer from irreproducible retention times and, therefore, could not be utilized
without a detection system. It was unclear if the reproducibility problem was due to the
mobile phase type146 or silver bleed, but inconsistent elution has been reported by other
authors132.
Following separation of fatty acyls with either normal phase or silver ion
chromatography the individual subclasses (eg. PFAMs or NAGs) can be further separated
to determine the distinct analytes present. This was achieved with C18 reversed phase
chromatography and detected with tandem MS.

The elution order followed the trends

observed with fatty acids eluted from reversed phase columns153. In general, the lipids
elute from shortest to longest acyl chain with one degree of unsaturation causing elution
to decrease by the equivalent of 2 carbons. For example, a C16:0 would elute at a similar

67

retention time to a C18:1. These so called “critical pairs” were able to be separated by
adjusting the gradient elution parameters and/or increasing the column theoretical plates.
For PFAMs, isobaric compounds (oleamide, elaidamide, and petroselaidamide) differing
only in double bond position were unit resolved using a 5 minute hold at 80% methanol
followed by a 5 minute linear ramp to 100% methanol. This resulted in LOD of 10 – 400
nM depending on the species. NAGs proved to be difficult to separate on standard C18
columns due to low solubility and increased interaction with the stationary phase. This
often resulted in double peaks and both higher peak broadening and tailing. Therefore, a
C30 substituted column and a fused-core C18 column with a reduced particle size were
employed to determine the optimum conditions for NAG separation. Of note, in our
hands NAGs were not found to ionize efficiently or reproducibly in positive ion mode,
thus, negative ion mode was used for all studies. The C30 column proved useful in
separation of saturated and monounsaturated NAGs with modest tailing, however, the
analysis time was undesirable when considering multiple dimensional LC. The 2.6 µm
particle size fused-core column was expected to reduce the analysis time, broadening, and
tailing factor. As expected, the analysis time was reduced by 6-fold, and peaks were
baseline resolved with minimal tailing. Similar to observations of PFAM separation,
NAG analysis time could not be reduced below 5 minutes and retain separation. Due to
the low ionization efficiency of these compounds the LOD was 1 µM for all species,
consequently, limiting the ability to detect biological levels.
Given the experimental limitations of silver ion chromatography, the normal
phase chromatography method was chosen as the preferred first dimension separation
method due to automation and high reproducibility. An offline approach was favored as

68

The analysis time by reversed phase separation could not be reduced sufficiently which
would lead to larger injection volumes from the first dimension. The small column
volume and flow rate of the second dimension would, thus, be incompatible for mixing
nonpolar solvents of the first dimension, causing a higher background noise.
Additionally fractionation of the NAG and PFAM peaks would lead to overall lower
moles being analyzed per unit time and, therefore, may obscure accurate quantitation. By
taking time to process samples between separation dimensions all of these caveats were
avoided. In summary, we developed an off-line MDLC system for analysis of PFAMs
and NAGs in vertebrate samples of complex lipid composition (see Chapter 4: Analysis
of Swiss-Webster Mouse and Sprague-Dawley Rat Tissue via Two Dimensional
Liquid Chromatography and Tandem Mass Spectrometry) for the highest
quantitation integrity.
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Chapter 4

PFAM and NAG Detection in Tissue Samples and
Implications for Future Studies
4.1. ABSTRACT
Primary fatty acid amides (PFAMs) and N-acyl glycines (NAGs) are polar lipids
that have been shown to be bioactive in mammals and humans. These compounds are
hypothesized to play an important role in bioregulation of physiological processes, such
as sleep and mood.

Likewise, aberrant metabolism of these lipids may be a diagnostic

tool for identifying disease.

A group of PFAM and NAG standards, ranging in carbon

chain length from 12 to 22 with various degrees of unsaturation, were separated by a
normal phase to isolate the PFAM and NAG subclasses. Reconstituted fractions were
further separated using reverse phase chromatography with gradient elution by methanol
and water. Components were detected by MRM mode to allow for selective detection.
The PFAMs were observed in positive mode as the [M + H] + peak and NAGs were seen
in negative mode as the [M – H]- ion. Heart, liver, and brain tissue obtained from wild
type Swiss Webster mice and Sprague-Dawley rats were analyzed via the developed
method to determine the biological levels of the target analytes. Samples from mice and
rats were found to have levels of PFAMs and NAGs at the periphery of the limit of
detection for the described method.

Other factors, such as tissue quality and use of

inhibitors were found to have a profound effect on sample detection. The knowledge
gained from this study has now poised future studies to further correlate the effect of
behavioral phenotypes on the biological levels of these bioactive lipids.
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4.2. INTRODUCTION
PFAMs are polar lipids that have established physiological properties and
neuroreceptor interaction (see Chapter 1: Metabolism, Physiology, and Analyses of
Primary Fatty Acid Amides). For example, exogenous application of low levels of
oleamide to cell lines expressing 5HTR subtypes 1A, 2A, and 2C potentiated the
receptors with maximal effects at 100 nM3-5. Functional studies observed maximum
potentiation of PFAMs with acyl tail length 16 to 22 with one degree of unsaturation near
the Δ9 position forming a hairpin-like configuration3,6,10. In addition to interaction with
serotonin receptors PFAMs have also been shown to modulate glycine 64, GABA5,10,64,66,
and cannabinoid receptors12,13, gap junctions71, and cellular calcium signaling71,72.
Oleamide and erucamide have been found at elevated levels in the cerebral spinal fluid of
sleep deprived rats, cats, and in hibernating squirrels suggesting a physiological role for
these PFAMs15,52,100,117. Other physiological effects induced by PFAMs include water
modulation87, food uptake18, promote angiogenesis55,56 hypolocomotion and decreased
body temperature17,54.
Degradation of PFAMs is accomplished by the enzyme FAAH and the
mechanism is well defined42-51. Anabolic pathways have been explored exclusively in
vitro and are still under debate. Proposed pathways include conversion of fatty-CoA
substrate to N-acylglycine (NAG) by cytochrome C27-29,154, BAAT31, and glycine N-acyl
transferase32,33. The NAG can also be formed by an N-acylethanolamine substrate being
converted by alcohol dehydrogenase36,38. All of the proposed anabolic pathways for
formation of PFAMs include the NAG intermediate being converted by peptidylglycine
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α-amidating monoxygenase (PAM)22-26,155,156 or cytochrome C. One notable exception
was demonstrated by Meuller et al. where the fatty-CoA was directly amidated to the
corresponding PFAM by cytochrome C27-29,154.
PAM is a bifunctional enzyme primarily responsible for the amidation of
glycinated peptides157-166. It is this amidation action that confers biological activity to the
otherwise inactive peptidylglycine. Due to this reflection, NAGs are largely believed to
be inactive intermediates in the anabolic pathway of PFAMs. The corresponding NAG
was found to be inactive in experiments on oleamide’s effect on gap junction
communication, supporting this hypothesis70.

Nonetheless, Bradshaw et al. have

investigated the distribution of NAGs in biological samples. Skin, lung, spinal cord,
kidney, and liver were found to have the highest concentration of select NAGs per weight
of dry tissue91. The approximate concentration range in these tissues was 100 – 1600
pmol/g.
Some reports exist of quantitation of PFAMs in biological samples, such as in
human luteal phase plasma2, cerebral spinal fluid of sleep deprived cats15,117, and lung,
kidney, liver, and brain of pig87. However, no comprehensive reports in a single species
are available such as those by Bradshaw and co-workers91. A broad, quantitative screen
of PFAM and NAG levels in biological tissues would aid in supporting proposed
anabolic pathways and investigating the role of these molecules in behavioral
phenotypes. Here we present an analytical strategy for quantitation of PFAMs and NAGs
in biological samples.
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4.3. MATERIALS AND METHODS
4.3.1 Chemicals
Methanol optima grade, formic acid optima grade, ammonium acetate, hexane,
dichloromethane, acetonitrile, and ammonium hydroxide were purchased from Fisher
Scientific (Fair Lawn, NJ, USA). Oxalyl chloride, oleic acid, erucic acid, petroselaidic
acid, heptane HPLC grade, methyl-tert-butyl-ether HPLC grade, isopropanol HPLC
grade, acetic acid, and anhydrous dichloromethane were from Sigma Aldrich (St Louis,
MO, USA). N, N-dimethylformamide, heptadecanoic acid, and eicosanoic acid were
purchased from Aldrich Chemical Company (Milwaukee, WI, USA).

Lauric acid,

myristic acid, palmitic acid, stearic acid, and docosanoic acid were purchased from Acros
Organics (New Jersey, USA). Elaidic acid was from MP Biomedical Inc. (Solon, OH,
USA) and linoleamide was purchased from Enzo Life Sciences (Ann Arbor, MI, USA).
Oleoylglycine,

Linoleoylglycine,

palmitoylglycine,

arachidonoylglycine,

and

arachidoylglycine were purchased from Cayman Chemicals (Ann Arbor, MI, USA).

4.3.2 Lipid Extraction and Normal Phase Separation
Tissue samples of either Swiss-Webster mice or Sprague-Dawley rat (generously
donated by Dr. Susan Amara) were weighed while frozen and kept on ice until extraction.
Tissue samples between 0.2 – 2.0 g were lipid extracted via a modified Folch-Pi
method86. Briefly, each sample was homogenized in 20 times the weight (in mL) of 2:1
chloroform:methanol with 1 mM indomethacin additive. Homogenized samples were
washed with 0.88% KCl and centrifuged at 2100×g for 60 minutes at 4 oC.

After

centrifugation, the aqueous layer was discarded and the remaining extract was transferred
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to a clean tube and dried under nitrogen. All glassware used was vapor silinized to
prevent lipid adhesion167 and any use of plastic was avoided due to contamination by
lipid slip additives168.

Each extracted sample was separated via normal phase

chromatography utilizing a YMC PVA-Sil column (4.6 × 250 mm, 5 µm particle size).
Gradient elution is carried out starting at 95 % mobile phase A (heptane with 0.5% v/v
methyl-tert-butyl-ether) and increasing linearly to 50% mobile phase B (methyl-tertbutyl-ether with 10% v/v 2-propanol and 0.2% v/v acetic acid) over 40 minutes with a
flow rate of 1 mL/minute (gradient developed by Kroniser and Johnson, unpublished).
Fractions were collected at 8 minute intervals and the time corresponding to NAG and
PFAM elution was collected, dried under nitrogen, and reconstituted in 100 µL of
methanol for further separation with reversed phase chromatography.

4.3.3 Reversed Phase Separation with MRM Detection of PFAMs and NAGs
PFAM and NAG eluent collected from the normal phase separation were further
analyzed by reversed phase chromatography. NAGs were separated with a Phenomenex
C18 fused-core column (4.6 × 100 mm, 2.6 µm particle size) using a gradient elution
starting with 70% methanol hold for 6 minutes, followed by a linear ramp to 80% over 8
minutes and a 1 minute hold at 80%, and ending with a 5 minute linear ramp to 100%.
Both methanol and water mobile phases were substituted with 10 mM ammonium acetate
to aid in ionization. The flow rate was 1 mL/minute and the injection volume was 5 µL.
Ionization was achieved with an ESI source operated in negative mode with optimized
parameters: fragmentor voltage 135 V, sheath gas flow 11 L/minute, nebulizer pressure
55 psi, nozzle voltage 500 V, capillary voltage 3500 V, drying gas flow 9 L/minute,
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drying gas temperature 275oC, and dwell time of 500 ms. MRM detection mode was
used to monitor the [M-H]- parent ion and 74 m/z product ion.
PFAMs were separated on a Zorbax RP C18 column (2.1 × 50 mm, 1.8 µm
particle size) with a gradient elution with methanol:water starting at 80% methanol hold
over 5 minutes, followed by a 5 minute linear ramp to 100% methanol, and a final 3
minute hold at 100%. The flow rate was 0.4 mL/minute, a 2 µL injection volume was
used, and 0.3% formic acid ionization aid was added to both mobile phases. PFAMs
were detected using an Agilent 6460 Triple Quadrupole Mass Spectrometer equipped
with an APCI source. Optimized detection parameters are as follows: gas temperature
325oC, vaporization temperature 325oC, gas flow 4 L/minute, nebulizer pressure 22 psi,
capillary voltage 3500 V, corona 4 µA, fragmentor 125 V, and dwell time 50 ms. MRM
detection was employed to monitor elution of the [M+H]+ parent ions and either product
ion 43 m/z for saturated components, or 55 m/z for unsaturated species.

4.4. RESULTS
Swiss-Webster mouse and Sprague-Dawley rat tissue was analyzed according to
quantity and availability, therefore, not all samples shown are from the same species nor
tissue type. Early attempts at extraction and analysis of PFAMs and NAGs from mouse
brain suffered from contamination, obscuring identification even upon blank subtraction
(Figure 4-1A). This contamination was found to be leaching from micropipette tips
during minor sample transfer steps in the Folch-Pi extraction steps. When all sample
contact with plastics was eliminated the contamination profile previously observed was
attenuated and sample peaks due to tissue extractions were evident (Figure 4-1B).
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Homogenization in SDS prior to Folch extraction was deemed unsuccessful since no
analytes were detected from the blank or tissue sample (Figure 4-1C). FAAH inhibitor,
indomethacin, was employed to prevent potential degradation (Figure 4-1D).

This

method of extraction showed the most promising results, with blank response near
baseline levels and detection of analytes in the tissue sample. 1 µM indomethacin was
included in all future extractions.

Figure 4-1. Analysis of contamination and use of inhibitors in tissue extracts. (A) Blank
extract using extraction solvents with no tissue present (B) Extraction of mouse brain
(black) overlayed with blank extract (red) excluding the use of plastic pipet tips in sample
preparation. (C) Mouse brain extract (black) versus blank extract (red) using SDS for
homogenization and all glass preparation. (D)Mouse brain extract (black) and blank
extract (red) by all glass Folch-Pi extraction with 1 µM indomethacin. All
chromatograms shown are analyzed by the reversed phase PFAM method

Rat hearts between 1.2 and 1.4 g were analyzed for the presence of PFAMs and NAGs
(Figure 4-2).

Three samples analyzed in the same week had very similar

chromatographic profiles but the same PFAMs were not present in all samples (Figure 42A, B, and C).

Two additional samples of rat heart were analyzed one week later with

very different chromatographic profiles and nearly no PFAMs detected (Figure 4-2D and
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E). Attempts to quantify the PFAMs observed in the heart samples gave a wide variation
of concentration ranges (~300 nM to 7 µM), while some were below the LOQ.

Figure 4-2. Analysis of (A-E) individual Sprague-Dawley rat hearts, and (F) Swiss-Webster
mouse brain with mid-brain removed. Peak labels show identified PFAMs using the C:XY
representation where C shows the acyl chain length, X is the degree of unsaturation, and Y is the
position of unsaturation. All unsaturation points are in the cis configuration unless otherwise
noted.

Mouse brain was tested because of the known interaction of oleamide with 5HTR. The
equivalent of 10 mouse brains (3.7206 g) was analyzed to ensure adequate sample size
(Figure 4-2F). All PFAMs identified in the sample were below the LOQ. No NAGs
were detected in any of the samples.
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Additional sample analysis displayed irreproducible chromatography, thus, the extraction
efficiency was tested over a 3 week period with approximately 1 g of rat heart per sample
(Figure 3). The first week extraction, following normal protocol, had a percent recovery
for an internal standard of 64% for the blank and 73% for the sample Figure 4-3A). The
baseline showed a higher variability in dynamic MRM mode for this sample,
consequently MRM mode was used in future analysis. Rat hearts for week 2 and 3
extraction experiments were homogenized and kept at 4 oC until analysis.

Figure 4-3. Time dependent extraction of individual Sprague-Dawley rat heart samples extracted
(A) the same week of homogenization, (B) one week after homogenization, and (C) 2 weeks after
homogenization. All samples were homogenized in 2:1 chloroform:methanol with 1 mM
indomethacin present. (B) and (C) were stored at 4 oC until analysis. Data for (A) was obtained
using dynamic MRM mode while (B )and (C) were collected with MRM mode.

Week 2 samples had a percent recovery of 52% for the blank and 49% for the sample
(Figure 4-3B). Week 3 samples were 43% recovery in the blank and the internal standard
in the sample solution was not detected (Figure 4-3C).
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Reproducibility issues continued after extraction efficiency studies. After normal phase
column regeneration protocols were conducted, rat liver was analyzed (Figure 4-4).
While each sample had similar chromatographic profiles, no PFAMs or NAGs were
detected.

All additional tissue analysis for rat brain, liver, and heart displayed no

measurable amount of PFAMs nor NAGs.

Figure 4-4. Analysis of Sprague-Dawley rat liver. Each figure (A-D) represents one replicate of
approximately 2 grams per sample. The peaks present to not match the retention time nor m/z for
any known PFAM determined with Agilent Mass Hunter Qualitative Analysis software.

4.5. DISCUSSION AND CONCLUSION
Brain, liver, and heart of Swiss-Webster mice and Sprague-Dawley rats were
analyzed for content of PFAMs and NAGs using an off-line normal phase and reversed
phase HPLC-MS/MS method. Initial sample extracts of mouse brain showed a high level
of contamination evident in both the sample and the blank. This contaminant was found
to be extractable lipids in plastic pipette tips (Figure 1A, B). When any tissue sample
was extracted and prepared using only glassware, and micropipette transfer steps were
eliminated, the blank and sample exhibited very different chromatographic profiles. The
addition of an FAAH inhibitor, indomethacin (IC50 = 100 µM)43, was used to prevent
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enzymatic degradation of the PFAMs and NAGs present. Addition of 1 mM inhibitor
acted to increase the sample signal compared to the blank (Figure 1C, D).
After contamination and inhibitor studies were complete samples were analyzed
for identity and quantity of select PFAMs and NAGs.

Some preliminary rat heart

samples appeared to have comparable chromatographic profiles, possibly indicating
similar composition (Figure 2A-E). Future extractions of rat heart failed to reproduce the
results obtained in Figure 2A-C.

In addition, the quantity and identity of PFAMs

observed varied greatly between samples.

Attempts to quantitate the observed PFAMs

yielded results ranging from 300 nM to over 7 µM, which could not be reconciled by
examining differences in % recovery between samples.
The extraction procedure was tested to determine if a longer extraction time could
increase the incidence of PFAMs or NAGs observed (Figure 3). None of the spectra
from week 1 to week 3 of extraction had any identifiable PFAMs or NAGs. Because the
signal intensities could not be directly compared the % recovery was used as a qualitative
measure of extraction efficiency. From week 1 to 3 the % recovery in both the sample
and the blank decreased. Reduction in the incidence of heptadecanoamide could be due
to a number of factors, including minimal enzymatic degradation or oxidative damage.
Therefore, future samples were homogenized, extracted, and dried down within 24 hours.
Over several months of sample preparation the internal standard was increasingly
not detected. This issue was resolved by normal phase column regeneration, which
removed column build-up.

The regeneration procedure was employed after

approximately 1 mL of sample extract was injected, or every 5-7 samples. After column
cleaning, analysis of rat liver was conducted (Figure 4A-D). Each sample appeared to
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exhibit similar chromatographs, however, no PFAMs or NAGs were identified. Indeed,
all subsequent analyses of brain, heart, or liver contained no measurable PFAMs or
NAGs.
Other authors have reported finding 0.1-5 pmol/100 µL (approximately 50 nM)
oleamide in cerebral spinal fluid15,117, and erucamide in pig lung, kidney, liver, and brain
between 0.5 and 12 ng/g ( intermediate value of 200 nM ) 87. These values fall just below
the LOQ and LOD for oleamide determined in our optimized system. With respect to
other PFAMs, the LOD range is from 10 – 400 nM. Thus, a minimum of 4 g of tissue
must be extracted to reach the LOQ for oleamide assuming 60% recovery. Separation of
4 g of tissue extract by the normal phase chromatography method developed will require
4 separate injections (approximately 11 hours) for a single tissue sample replicate due to
sample viscosity. Additionally, large sample sizes tended to exhibit a white cloudy film
after reconstitution in methanol prior to reversed phase analysis. This film was only
transparent when dissolved with 2:1 chloroform:methanol. Unfortunately, this solvent
caused jamming and clogging of the auto-injection system.
hindered quantitation was the system LOD and LOQ.

One other factor that

The system was optimized,

however, there was little difference between many of the LOD and LOQ suggesting that
ion transmission dropped off rapidly.
In conclusion, the development of a MDLC-MS/MS method allowed for the
analysis of vertebrate tissue samples. The incorporation of an internal standard to the
extract aided in the validation of correct fraction collection from the 1 st dimension and
allowed for stability comparison between samples.

From these analyses several

important factors in quantitation of PFAMs and NAGs in these samples was determined.
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The use of plastics was found to contribute contaminants to the extract and, thus, the use
of glass in the preparation was advantageous in reducing background. The addition of
inhibitors to prevent degradation of PFAMs by FAAH was found to increase the
detection of components in the extract.

Additional factors in ensuring reliable

quantitation, such as tissue quality and data analysis considerations, are discussed in the
following section.

4.6. PROJECT OUTLOOK AND CONCLUDING REMARKS
It is clear, even with careful method selection and sample processing
consideration, that quantitation of trace levels of the PFAM and NAG subclasses propose
a challenge for conventional separation and detection methods. Several factors were
found to have a profound impact on analysis and additional experimental methodology
should be further contemplated. One factor found to influence detection was the use of
tandem mass spectrometry.

Many of the PFAMs and NAGs investigated for

determination of LOD and LOQ revealed a steep loss of signal. For NAGs this was
observed at 1 µM and for PFAMs it was variable between 100-400 nM (see Chapter 3:
Chromatographic Separation Methods for Fatty Acyls). A similar signal drop-off for
PFAMs is observed in GC-MS with electron ionization (Davic, A. P., personal
communication) and, thus, the LOD seems to be an inherent limitation of these analytes
versus quality of MS instrumentation available. This MS LOD may only be capable of
being improved for instrumentation with ion trapping capabilities.
Other experimental parameters of consideration are quality and tissue and
extraction conditions. Tissue should be excised immediately after sacrifice and flash

82

frozen in liquid nitrogen within minutes to prevent chemical alteration. If the excised,
frozen sample is not processed immediately it should be stored frozen at -80oC. Between
removal and usage that sample should not be allowed to thaw until extraction is
complete. In addition, the homogenization procedure should be carried out in ice-cold
extraction solvents to limit enzymatic hydrolysis. The addition of indomethacin to the
2:1 chlorofrom/methanol solvent was found to have a positive effect on detection of
components in extracted tissue samples.

This molecule, while shown effective in

reducing FAAH activity, is not an FAAH specific inhibitor, but affects degradation via
the COX-2 pathway. A more specific inhibitor should be chosen in future studies to
ensure hydrolysis of the analytes is not problematic. Since the FAAH active site is a
catalytic triad containing Ser-Ser-Lys, PMSF may be an appropriate choice and has
documented inhibition properties on FAAH43,44,47.
The last major consideration of PFAM and NAG quantitation should be data
analysis. Endogenous PFAM concentrations have demonstrated fluctuation related to
sleep cycle15,52,117 and many other mundane events, such as food intake18, may alter these
lipid levels.

Therefore, it is not improbable that environmental impact will cause

genetically identical animals to display a range of endogenous concentrations. Given
these experimental implications the data analysis method is of utmost importance. In
evaluation of disease models or behavioral phenotypes, principle component analysis is
used to differentiate aberrant levels of biomarkers. Likewise, this approach should be
utilized here to determine the range of endogenous variation. These data can then be
compared to numerous animal models of disease and behavior to determine if any
correlation can be ascertained.
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In conclusion, experimental factors, including tissue quality, extraction
preparation, and data analysis methods will need to be altered and rigorously conducted
to render reliable quantitation results.

MS/MS, while a highly sensitive detection

method, was not sufficient in this study given the characteristic limitation of PFAM ion
transmission. Currently our laboratory is working on a new PFAM detection platform
utilizing microdroplet derivitization and laser induced fluorescence detection. In this
detection system separated eluents from a chromatographic system are mixed with
fluorescent derivitization reagents in nano-droplets formed on a microchip by
perpendicular, fast flow of an immiscible phase. The design of the microchip channels
enhances mixing of the fluorescent reagents via turbulent convection. The fluorogen tags
in this method have no native fluorescence, a large stokes shift, and are selective for
primary amines. The un-optimized LOD for this system is in the attomole range (Davic,
A. P., personal communication) compared to the above 150 femtomole LOD. This lower
LOD combined with the selectivity of the derivitization will enable quantitative
measurement of PFAMs with a reduced use of tissue. Therefore, changes in PFAM
levels could be tested and compared to behavioral phenotype experiments to determine
the significance of these bioactive signal lipids on physiology.

The use of fluorescent

tagging and sub-attomole detection with microdroplet reaction and laser induced
fluorescence platforms being undertaken in our laboratory will provide a more effective
means of determining the endogenous trace concentrations of these bioactive lipids.
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Appendix 1

Palmitoylethanolamine Stability in Fluorocarbon
Emulsions: A Delivery System for Treatment of
Chronic Pain

A.1. ABSTRACT
Palmitoylethanolamine (PEA) is an endogenous molecule that has been found in a wide
variety of sources including plants, like peanut and soy, as well as various vertebrates.
Although PEA does not directly interact with known cannabinoid receptors, it has
documented cannabimimmetic effects. Treatment or ingestion of this compound is known
to produce a myriad of potentially advantageous physiological responses, most notably
anti-inflammatory and analgesic effects. PEA was incorporated into nano-emulsions
containing fluorocarbon with the intent to trace drug delivery in vivo. A selective and
sensitive method was developed utilizing HPLC-MS/MS with MRM detection of the [M
+ H]+ parent ion and protonated ethanolamine product ion to determine the incorporation
and stability of PEA in these nano-emulsions. Detection and quantitation limits for the
optimized method reached 1 femtomole.

A.2. INTRODUCTION
N-acyl ethanolamines (NAEs) are congeners of fatty acids containing an
ethanolamine moiety and are a subclass of the fatty acyl lipid group outlined by Fahy et
al.169 This group of lipids is biosynthetically produced by cleavage of membrane N-acyl
phosphatidylethanolamines to NAEs by a phospholipase D170-172. Deactivation of these
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compounds is achieved by fatty acid amide hydrolase (FAAH) and N-acylethanolaminehydrolyzing acid amidase (NAAA), preferential for anandamide (AEA) and
palmitoylethanolamine (PEA), respectively (for a review see Tsuboi et al173), resulting in
ethanolamine and the corresponding fatty acid.

While both of these enzymes degrade

NAEs they are structurally and functionally dissimilar. FAAH and NAAA show no
sequence homology and FAAH hydrolyzes compounds optimally at pH 8.5-10, whereas
NAAA is most active at pH 4.5-5. Fluorescent tagging experiments of these degradative
enzymes show a membrane-like distribution of FAAH and a dispersal of NAAA
reminiscent of cytosolic or lysosome residence.
NAEs are endogenous compounds have been characterized in a wide range of
species and tissues. Of the discovered NAEs, the endocannabinoid AEA is the most
studied. AEA was first isolated from porcine brain and described by Devane et al.174 as
an endogenous compound that binds to the cannabinoid receptor, most notorious for its
interaction with the psychoactive component in cannabis. The extensive amount of
information available on AEA is beyond the scope of this text and will not be covered in
detail, except in comparison to PEA (additional information on AEA is reviewed in 113115

).
PEA was first described in 1954 as a compound in whole egg yolk and alcohol

soluble fractions of egg, but not in protein or acetone fractions, that was found to reduce
mean swelling index in joints of guinea pigs and pig weanlings when challenged with
anaphylactic arthritis175. The structural identity of the active component in egg was not
identified until several years later by Kuehl et al.176 Since its discovery, PEA has been
identified in a wide variety of plant and animal sources, including peanut oil and soy
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lechtin177, sea urchin ovaries178, central nervous system of leech179, several species of
bivalve molluscs180, pig181, cow181, sheep181, mouse182, rat183,184, and human121.
Concentrations of NAEs in these tissues are reported in the pmol/g range.
The most notable physiological properties of PEA identified to date are its
propensity for anti-inflammatory and analgesic effects. In models of neuropathic pain
induced by chronic constriction injury treatment with subcutaneous injections of
30 mg/kg PEA attenuated pain response from noxious and non-noxious stimuli in wild
type mice185. Additionally, PEA administration prevented changes in number of fibers,
myelin thickness, axon diameter, and reduced 50% of edema in nerve fibers. Injections
of PEA over a 14 day period also reduced the number of inflammatory infiltrate cells
observed at the injury site. These anti-inflammatory and protective effects were not
observed in PPARα null mice. LoVerme and coworkers found similar results for PEA
treatment in chronic constriction injury model of neuropathic pain 186.

They also

described a diminished nociceptive behavioral response to formalin, magnesium sulfate,
and carreegnan induced hyperalgesia. Reduction of edema was not evident until 1 h post
injection, although analgesic effects were evident shortly after treatment. Attenuated
pain response was abolished by CB2 antagonist, SR144528, and inhibitors of calcium
mediated potassium channels.

CB2 knock-out mice were still responsive to anti-

inflammatory and analgesic effects of PEA; providing evidence that PEA is not an
endogenous ligand for CB2 receptors, but exerts cannabimimetic properties. Paw
withdraw latencies of mice administered a single dose of PEA versus those treated with
the drug for 7-14 days showed similar results, both of which were higher than mice
receiving vehicle, suggesting that PEA does not prompt a developed tolerance over the
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time period tested. In line with previous reports, formalin and carrageenan induced
edema and hyperalgesia were reduced with PEA treatment 187. PEA was also shown to
diminish the number of mast cells present, as well as plasma extravasation caused by
substance P. Mast cells were previously shown to be down modulated by exogenous
PEA application188. These effects were revealed to be dose-dependent. Injection of
palmitic acid and ethanolamine were ineffective, proving PEA, and not its metabolites,
elicited the observed response187.

Interestingly, PEA and AEA co-administered in

formalin induced pain models were found to be 100 fold more potent than either
compound alone189.

These synergistic effects between PEA and AEA were also

demonstrated by enhanced relaxation of rat mesenteric arteries78. Attenuated response to
pain by AEA and PEA were even more potent when delivered locally, rather than
systemically189. Observed analgesia was reversed by CB2 antagonist SR144528; CB1
antagonist and opioid antagonist, naloxone and SR141716A, were ineffective.
Additionally, a selective inhibitor of the main degradative enzyme of PEA, NAAA, was
shown to have similar effects as PEA administration in a carrageenan pain and
inflammation model190. Inhibitors of FAAH, the main catabolic enzyme of AEA, had no
effect. This data suggests that, while some effects of endogenous NAEs may be ascribed
to the so called “entourage effect” (a hypothesis that endogenous NAE properties are due
to the increased half-life of AEA), these lipids clearly have their own properties distinct
from AEA.

PEA treatment has been reported to reduce lipopolysaccharide-induced

nitric oxide production in RAW264.7 macrophages191. Thus the analgesic and antiinflammatory properties of PEA may be attributable to attenuation of nitric oxide
production, which is a known pro-inflammatory.
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Curiously, other reports of inflammation models and various disease states have
shown an endogenous modulation in PEA and other congeners. Intraperitoneal injections
of cadmium chloride in Wistar rat testes exhibited a drastic increase in PEA,
stearoylethanolamide (SEA), and AEA that was time-dependent with total NAE levels 25
fold higher at 9 h post injection183.

In patients with osteoarthritis and rheumatoid

arthritis, diseases that involve pain and inflammation of the joints, levels of PEA, and to a
lesser extent OEA, were found to be dramatically reduced compared to control groups 192.
Examination of the CSF of patients with schizophrenia found the PEA and AEA were 2
fold higher versus control groups121. Tests of stress and anxiety found PEA and OEA
concentrations in the serum increased when patients were exposed to a stressful
situation122. Additionally, in patients characterized as having chronic wide spread pain
and chronic neck and shoulder pain that, generally, pain score intensities correlated
negatively with PEA and SEA levels120. It is unclear in the disease states presented here
if aberrant levels of NAEs are due to metabolic defects or are modulated as a downstream response.
There is some evidence that indicates elevated levels of PEA and other NAEs act
in

a

protective

manner.

PEA,

SEA,

oleoylethanolamine

(OEA),

and

linoleoylethanolamine were found to increase in infarcted canine myocardium193. It is
also known that PEA accumulates in ischemic tissues and protects cerebellar granule
cells against glutamate excitotoxity194. Addition of AEA was found to antagonize the
protective effects of PEA in glutamate excitotoxicity. Exogenous application of PEA (1 –
1000 nM) reduced the number of microglial cells and protected dentate gyrus granule
cells in excitotoxically lesioned hippocampal slice cultures. These effects were abolished
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by PPARα, but not PPARγ, antagonists195. In models of ischemia, administration of 10
mg/kg PEA to rats, either 30 min before or during middle cerebral artery occlusion,
significantly reduced the infarct volume and neurological deficit score 196.

Several

proteins found to be up regulated in ischemia had reduced levels in animals receiving
PEA pretreatment. Rats which were given AM404, an NAE uptake inhibitor, were found
to have larger infarct volumes and higher neurological deficit scores.

Again, PEA and

AEA levels were enhanced in the spinal cord of mice in an animal model of multiple
sclerosis182. Intravenous injections of PEA and AEA improved spasticity within 10-30
minutes. PEA was found to dose-dependently reduce impairment, normalize learning
profiles and working memory in an animal model of Alzheimer’s disease 197. As with the
anti-inflammatory and analgesic effects mentioned previously, learning and memory
benefits associated with PEA treatment were absent in PPARα null mice.

Finally,

intraperitoneal injections of PEA (EC50 8.9 mg/kg) in maximal electroshock seizure tests
were found to have an anticonvulsive property198. In chemical induced seizures, PEA
was

only

effective

against

tonic

convulsions

of

pentylenetetrazol

and

3-

mercaptropropionic acid. Overall, PEA reduced lethality associated with convulsions.
NAEs exert other cannabimimmetic effects, such as alteration of food uptake.
Guinea pigs and rats deprived of food for 12-18 h had elevated levels of PEA in the brain
and liver199. In contrast to AEA18, SEA, PEA, and OEA intraperitoneal injection were
found to decrease food intake in starved rats200 and mice201. Food deprivation acted to
reduce the biosynthesis of OEA200. The anorexic effect of OEA was not affected by CB1
or CB2 antagonists, SR141716A and SR144528, respectively. Intracerebroventricular
injection did not cause a decrease in food consumption, indicating that the anorexic
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effects are not mediated by the central nervous system200.

Reduction in food

consumption invoked by treatment with SEA (up to 100 mg/kg) was not accompanied by
sedation, illness, or diminished motility and body temperature. No other changes in
glucose, triglycerides, or cholesterol levels were apparent. Administration of stearic acid
did not alter food consumption versus controls. Interestingly, OEA and PEA were found
to increase in the white adipose tissue of Wistar rats exposed to 4 oC for up to 6 h202.
Elevation in NAEs was accompanied by increases in N-acyl transferase, but not FAAH.
Exposure of adipocytes to noradrenaline and isoproterenol, beta-adrenergic agonists,
elevated levels of OEA and PEA in cells while, the beta-adrenergic antagonist, pranolol,
blocked the increases.
Due to the prevalence of these molecules in biological systems and the discovery
of multiple orphan G protein coupled receptors, NAE binding has been investigated in
orphan GPR55 and GPR119 receptors. Sequencing of GPR55 revealed that rat and
mouse shared 75 and 78% identity, respectively, with human203. GPR55 shares relatively
low sequence identity with CB1 and CB2 receptors, 13.5% and 14.4%, respectively204.
mRNA levels were highest in the gastrointestinal tract, adrenal gland, central nervous
system203, and large dorsal root ganglion neurons204. Expression of GPR55 in HEK293
cells discovered that AEA, OEA, and PEA were able to bind with EC50 values of 18, 440,
and 4 nM via radiolabeled binding assays with GTPγS. Surprisingly, THC was able to
bind at an EC50 of 8 nM, which is of higher affinity than its binding with CB1 or CB2
receptors, suggesting this orphan receptor may be a newly discovered cannabinoid
receptor203,205. Exogenous application of AEA and THC to HEK293 cells expressing
GPR55 acted to increase intracellular calcium and reversibly suppress M type potassium
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currents204. PEA had no effect on calcium release. GPR119 is expressed mainly in the
gastrointestinal tract, pancreas, and brain206. AEA, SEA, OEA, and PEA were shown to
activate human and mouse GPR119 in a yeast fluorescence assay, with OEA being the
most potent. Due to this orphan receptors’ localization in the gastrointestinal tract and its
affinity for OEA, this receptor-ligand interaction was hypothesized to mediate the
anorexic effects observed with OEA treatment and indeed synthetic, selective agonists of
GPR119 produced a hypophagic effect.
Here we present method development and analysis of PEA stability in
fluorocarbon nanoemulsions by HPLC-MS/MS. Fluorocarbon nanoemulsions have been
previously demonstrated as drug delivery vehicles for poorly soluble drugs, such as the
anti-inflammatory, celecoxib207-209.

Following this rationale, PEA formulation into

fluorocarbon nanoemulsions was undertaken.

Here we present development of a

sensitive analytical methodology to track incorporation and stability of PEA in new
fluorocarbon nanoemulsion formulations. These studies were undertaken in light of the
vast evidence for PEA as an analgesic with the intent to deliver and potentially track drug
distribution in vivo in preclinical models of chronic pain. Tracking drug distribution will
aid in determining how much of the drug reaches inflammation sites and how quickly it is
degraded in vivo.

A.3. MATERIALS AND METHODS
A.3.1 Chemicals
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Methanol, optima grade, chloroform, HPLC grade, and formic acid, optima grade
were purchased from Fisher Scientific (Fair Lawn, NJ, USA). Palmitoylethanolamine
was purchased from Tocris Bioscience (Bristol, UK). Fluorocarbon nano-emulsions were
kindly provided by Dr. J. Janjic (Department of Pharmacy, Duquesne University,
Pittsburgh, PA)
A.3.2 Methods
PEA extracts were crudely separated on a Zorbax RP C18 column (2.1 × 50 mm,
1.8 µm particle size) with isocratic elution of 80:20 methanol:water containing 0.3%
formic acid as an ionization aid. The flow rate was 0.4 mL/minute, a 2 µL injection
volume was used, and the eluent was detected using an Agilent 6460 Triple Quadrupole
Mass Spectrometer equipped with an ESI source. Optimized detection parameters are as
follows: gas temperature 275oC, sheath gas temperature 300oC, gas flow 5 L/minute,
sheath gas flow 11 L/h, nebulizer pressure 45 psi, capillary voltage 4000 V, nozzle
voltage 450 V, fragmentor 135 V, and dwell time 200 ms.

MRM detection was

employed to monitor elution of the [M+H] + parent ion at 300 m/z and product ion 62 m/z
at a collision energy of 20 V.

A.4. RESULTS
PEA was directly infused using at Harvard Apparatus syringe pump at a flow of 0.2
mL/min in a 6460 Agilent Triple Quadrupole to determine the compound ionization and
optimum collision energy (Figure A-1A). A crude separation method was developed to
reduce ion suppression effects and determine the most sensitive ESI ionization
parameters and MRM detection (final method described in Section 3.2 Methods). The
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CID patterns were found to consist of [M+H]+ parent ion, the loss of a hydroxyl group to
yield the product ion 283 m/z, and fragmentation of the head group giving a protonated
ethanolamine moiety at 62 m/z (Figure A-1B). The linear range was found to be 500 pM
- 80 nM and the LOD and LOQ were equivalent at 1 femtomole (Figure A-2).

Figure A-1. (A) CID of 1 µM PEA directly infused using a Harvard Apparatus
syringe pump connected to a 6460 Agilent Triple Quadrupole MS equipped
with ESI operated in positive mode. (B) Proposed fragmentation of PEA
showing loss of a hydroxyl at 283 m/z and a protonated ethanolamine at 62 m/z.
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Figure A-2. (A) Concentrations of PEA from 500 pM to 80 nM were used to
determine the linear range with isocratic elution in 80:20 methanol/water and an
ESI ionization and MRM detection on a 6460 Agilent Triple Quadrupole using
the parent ion 300 m/z and product ion 62 m/z. (B) The expanded calibration
curve from 500 pM to 7 nM to show linearity in the lower range.

Nano-emulsions

were

freeze-thawed,

extracted

with

a

solution

of

2:1

chloroform/methanol (HPLC grade), and an aliquot of the organic phase diluted in
methanol to give an expected final concentration within the linear range. As in earlier
work, the use of plastic was avoided in the sample preparation process due to use of
extractable lipids in the plastic manufacturing process168. Early formulations of the nanoemulsions contained olive oil to aid in the solubilization of lipophilic PEA, therefore a
control sample was prepared with equivalent concentrations of olive oil to determine the
possible interferences. The presence of olive oil exerted no negative effects on PEA
detection evidenced by matching expected and measured values (Table A-1). Regardless,
emulsions Emulsion 1 and 2 contained approximately 10 fold lower detected
concentrations than those expected.

Further avenues were explored, such as
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measurement of PEA in the supernatant versus the pellet of freeze-thawed samples,
increasing the concentration of the final sample from 50 to 500 nM (Table A-1), and
addition of a normal phase pre-separation step (data not shown).

Pre-separation of

emulsions compared with a control sample did not increase levels of detection. Addition
of ethanol to emulsions Emulsion 3 and 3F (5F is a microfiltered sample identical to
Emulsion 3) greatly improved the ability to detect PEA, although, the microfiltered
sample showed an almost 2 fold lower than expected value. Ethanol was added only to
aid in solubility of the drug into a surfactant mixture and was evaporated from the final
sample prior to testing. The same Emulsion 3 and 3F samples were tested again one week
post preparation and PEA levels were found to decrease significantly. Lower levels of
PEA after one week suggested degradation of PEA in the emulsion.
Sample
Control
Emulsion 1
Emulsion 2
Emulsion 1
Supernatant
Pellet
Emulsion 2
Supernatant
Pellet
Emulsion 3
Emulsion 3F
Emulsion 3 –
1 week post preparation
Emulsion 3F –
1 week post preparation

Expected (nM)
75
500
500

Measured (nM)
72 ± 2
58 ± 1
59 ± 1

50
0

4±2
5±2

50
0
50
50

5±2
3±2
45 ± 1
29 ± 1

50

21 ± 2

50

8±2

Table A-1. Quantitation of PEA in nano-emulsions. The control sample contained
concentrations of PEA and olive oil equivalent to those present in the prepared
emulsions. The expected concentration values are those of the final sample after dilution
for HPLC-MS/MS. F indicates samples which were filtered after preparation. Measured
values show those obtained by peak integration and interpolation from the prepared
calibration curved. Statistical values were obtained using the formula for standard error
in the least squares fit.
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A.5. DISCUSSION AND CONCLUSION
We have successfully determined parameters of a sensitive detection method for
PEA. The linear range of 500 pM - 80 nM was chosen due to the high linearity of fit
which were greater than 0.9995 (R2). The LOQ and LOD for PEA with this method was 1
femtomole (500 pM), which is equivalent to those being currently reported for detection
of NAEs210-212. Analysis of fragments generated by CID identified a quantitative product
ion at 62 m/z matching the mass of a protonated ethanolamine ion. This finding indicates
that NAEs can be sensitively and selectively analyzed as the ethanolamine moiety gives a
unique point of identification over other lipid classes that frequently yield indistinct acyl
fragments.

Analysis of nano-emulsions by this method proved challenging as the

measured concentration was always less than expected based on the amount of PEA
added to initial samples. This could be explained by the strong surfactants used in the
dissolution of PEA in the aqueous based solution, since critical micelle index may not
have been sufficiently exceeded, thus, impeding the extraction process. Another factor
obscuring detection of PEA in nano-emulsions could be the storage or preparation
processes. Chemical information available on PEA indicates that this material is light
sensitive and therefore stocks or emulsions left in contact with light may have degraded.
This may explain the decrease in PEA detection observed of samples 1 week post
preparation. The process of freeze-thawing the emulsion before extraction was necessary
to remove the fluorocarbon component. This was the layer referred to previously as the
“pellet”. Stock solutions of PEA prepared in a 2:1 chloroform/methanol solution and
stored at -80oC tend to irreversibly crystallize, signifying degradation (personal
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observation). It is possible that repeated freeze-thawing events intended to purify the
sample may cause degradation of the active component.
In future analyses of nano-emulsions and animal treatment with such, several
important factors should be considered. Samples prepared with PEA should be stored in
a location where light exposure is limited. Optimum storage temperature, either room
temperature or chilled, would need to be determined with additional stability
experiments. Based on previous observations, freeze-thawing of emulsions should be
avoided to preserve the chemical integrity of the sample. Due to the unreactive nature of
fluorocarbons and use of a selective MRM method it is likely that the presence of this
component will not be problematic for the detection or conservation of instrumentation
hardware. As surfactant micelle strength may be problematic, matrix conditions should
be carefully selected. Many current reports of animal treatment with PEA have employed
a mixture of tween 80 and polyethylene glycol or PBS with a final dilution in sterile
saline to 20:10 v/v182,185,197. Therefore, it may be of interest to determine PEA stability in
a common formulation currently used in in vivo experimentation.

Additional

considerations included brand of extraction solvents, SPE column type, and treatment of
tissue samples post-excision.

A recent report demonstrated that the brand of SPE

column, with identical packing material, resulted in astonishingly different recoveries of
NAEs213. This finding carried over into the brand of chloroform used, where some
brands resulted in chlorination of unsaturation points, thereby, obscuring true levels of
NAEs (OEA in particular). While PEA will not be affected by chlorination, these authors
provide great evidence for the importance of rigorous method development.

Final

concerns are due to post-mortem quantitation of NAEs in animal samples. Several
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authors have described an increase in levels of measured NAEs post-mortem in tissue
exposed to ambient conditions180,181 and generally in necrotized tissue193,194. Schmid et
al. reported a linear increase in levels of PEA, OEA, SEA, and AEA with time spent at
ambient temperature post-mortem181. Increases were dramatic with 37, 33, and 72 fold in
pig, sheep, and cow at 22 h ambient temperature. This finding was corroborated by Sepe
with substantial increases in PEA, OEA, AEA, and SEA in bivalve molluscs, but not
boiled mollucs, at increasing time at ambient conditions180. Therefore, excised animal
tissue should be used immediately or quickly stored at -20oC. Extractions should be
carried out in the shortest time frame possible with ice cold solvents until residual matter
can be removed. It would also be prudent to consider the use of enzyme inhibitors for
both biosynthesis and degradation of the desired analytes.
In summary, PEA is a lipophilic molecule with a long history of physiological
benefits, including anti-inflammatory and analgesic properties. As this compound is
endogenously produced, it appears to have few negative side effects that have been
reported in in vivo tests to date. It is, therefore, an attractive candidate for treatment of
afflictions of chronic pain and inflammation. Here we have described a method with
sensitive and selective detection of this endogenous compound. Current nano-emulsions
analyzed have proved troublesome in the detection and stability of PEA. Even though
biosynthesis is prevalent, ex vivo preparation is complicated by its lipophilic nature.
Nevertheless, the small considerations in sample preparation mentioned previously may
prove invaluable in correcting stability hurdles experienced thus far. Additionally, oral
dosage, though less effective, has proven successful. Tracking of drug delivery in a solid
form may be accomplished with enriched radiolabeled PEA.
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While small scale

experimentation would be initially expensive; this would not be necessary to carry into
clinical settings.

Therefore, PEA proves to be a viable treatment strategy with an

optimistic future for alleviating individuals afflicted with chronic pain.
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